ClinicalTrials.gg
CompletedNCT02564042Updated Nov 13, 2017Results posted

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

A Phase 2 interventional study of GSK2894512 1% Cream and GSK2894512 0.5% Cream in Psoriasis, sponsored by GlaxoSmithKline. Completed at 46 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
7th of 19
227 · median 58
Started
2015
the only one that year
Phase 2
3 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
3 of 19
GlaxoSmithKline

Among the 19 studies testing tapinarof in Psoriasis, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque psoriasis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and dosing frequency in future clinical safety and efficacy studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all psoriasis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adult males and females subjects with plaque psoriasis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Double blind
  • Dose-finding
  • Vehicle-Controlled
  • GSK2894512
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 to 65 years of age inclusive, at the time of signing the .
  • Confirmed clinical diagnosis of chronic stable plaque psoriasis for >=6 months.
  • Body surface area involvement >=1% and \<=15%, excluding scalp, at Screening and Baseline.
  • A PGA of psoriasis score >=2 at Baseline.
  • One target plaque located on the trunk or proximal parts of extremities (excluding knees, elbows, and intertriginous areas) that is at least 3 (centimetre) cm х 3 cm in size at Screening and Baseline with a severity representative of the subject's overall disease.
  • A female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin test), not lactating, and at least one of the following conditions applies: Non- defined as: 1) Pre-menopausal females with one of the following procedures documented: tubal ligation; hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; bilateral oophorectomy. 2) defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone and estradiol levels consistent with menopause and falling into the central laboratory's postmenopausal reference range is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt are required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment; Reproductive potential and agrees to follow one of the options listed in the modified list of highly effective methods for avoiding pregnancy in females of reproductive potential from 30 days prior to the first dose of study medication and until (at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer) after the last dose of study medication and completion of the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  • Any sign of infection of any of the psoriatic lesions.
  • A history or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, may interfere with the subject's completion of the study.
  • Known to the study treatment , or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation.
  • Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of surface antigen, or positive antibody test result within 3 months of screening.
  • Liver function tests: >=2x (ULN); alkaline phosphatase and >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • >=450 milliseconds (msec) or QTc >=480 msec for subjects with bundle branch block.

NOTES: The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), with machine over-read. The QTc should be based on a single obtained over a brief recording period. If QTc is outside of the threshold value, triplicate ECGs may be performed with the QTc values averaged.

  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 4 weeks prior to the baseline visit and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the subject's psoriasis.
  • Used any of the following treatments within the indicated before the baseline visit: 1) 12 weeks or 5 half-lives (whichever is longer) - biologic agents (eg, 24 weeks for alefacept, 12 weeks for etanercept, 15 weeks for ustekinumab); 2) 12 weeks - oral retinoids (eg, acitretin or isotretinoin); 3) 8 weeks - cyclosporin, interferon, methotrexate, other systemic or immunomodulating agents, or psoralen plus UVA light treatment; 4) 4 weeks - systemic or adrenocorticotropic hormone analogs; 5) 2 weeks - immunizations; drugs known to possibly worsen psoriasis, such as beta-blockers (eg, propranolol), lithium, iodides, angiotensin-converting enzyme inhibitors, and indomethacin, unless on a stable dose for >12 weeks; 6) 2 weeks - topical treatments: corticosteroids, immunomodulators, anthralin (dithranol), Vitamin D derivatives, retinoids, or coal tar (used on the body).
  • Participated in a clinical study and received an product within the following time period prior to the baseline visit: 4 weeks, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
  • History of alcohol or other substance abuse within the last 2 years.
  • Participated in a previous study using GSK2894512 (or WBI-1001).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    GSK2894512 1% cream twice daily

    Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram \[mg/g\]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).

    Drug: GSK2894512 1% Cream

  • Experimental
    GSK2894512 1% cream once daily

    Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).

    Drug: GSK2894512 1% Cream

  • Experimental
    GSK2894512 0.5% cream twice daily

    Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).

    Drug: GSK2894512 0.5% Cream

  • Experimental
    GSK2894512 0.5% cream once daily

    Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).

    Drug: GSK2894512 0.5% Cream

  • Placebo comparator
    Vehicle cream twice daily

    Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).

    Drug: Vehicle cream

  • Placebo comparator
    Vehicle cream once daily

    Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).

    Drug: Vehicle cream

Interventions

  • 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

  • 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

  • DrugVehicle cream

    White to off-white vehicle cream base to be applied topically

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week 12

    The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. The analysis was performed on modified intent-to-treat (mITT) Population which comprised of all randomized participants except those enrolled at center ID 220008.

    Time frame: Baseline and up to Week 12

Secondary outcomes

  1. Percentage of Participants With >=75 Percent Improvement in Psoriasis Area and Severity Index (PASI) From Baseline to Each Study Visit

    The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0 to 4) and the % BSA affected was scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. Higher scores indicated more severe disease. The percentage of participants with \>=75% improvement in PASI from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  2. Percentage of Participants With a Minimum 2 Grade Improvement in PGA Score From Baseline to Each Study Visit

    The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a minimum 2-grade improvement from Baseline for each study visit were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  3. Percentage of Participants With a PGA Score of 0 or 1 at Each Study Visit

    The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a PGA score of 0 or 1 from Baseline at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 16

  4. Mean Change in Percent of BSA Affected With Psoriasis From Baseline to Each Study Visit

    The extent of BSA affected by psoriasis is a general indicator of disease severity and was measured throughout the study. The extent of BSA to which study treatment was applied was also recorded. For the purpose of approximate clinical estimation, the total palmar surface of the palm plus 5 digits was assumed to be approximately equivalent to 1 percent BSA. Assessment of BSA affected with psoriasis was performed separately for four body surface regions: the head, the upper extremities, the trunk and the lower extremities, corresponding to 10, 20, 30 and 40 percent of the total body area, respectively. The mean change in percent BSA affected from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  5. Mean Change in PASI Score From Baseline to Each Study Visit

    The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of BSA affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0=None to 4=Severe) and the percent of BSA affected is scored on a 7-point scale (0=0% involvement to 6=90-100%) for each of 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. PASI score ranged from 0=no psoriasis to 72=worse psoriasis. The mean change in PASI score from Baseline was summarized for each study visit. Baseline was the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  6. PGA Scores at Each Study Visit

    The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean of PGA scores at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 16

  7. Mean Change in PGA Score From Baseline to Each Study Visit

    The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean change in PGA scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  8. Mean Change in Individual Target Lesion Grading Scores From Baseline to Each Study Visit

    A single target lesion of at least 3 centimeter (cm) x 3 cm was selected at Baseline. For the selected lesion, the severity of erythema, scaling and plaque thickness (induration) was assessed by the investigator on a 5-point scale ranging from 0=none to 4=severe. The mean change in individual grading scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  9. Mean Change in Weekly Average Itch/Pruritus Numeric Rating Scale (NRS) From Baseline to Each Study Visit

    The participant reported itch severity was obtained from the response of the participants to the itch NRS item in the psoriasis symptom diary (PSD). PSD was developed to assess daily self-reports of psoriasis symptoms and the functional impact related to the underlying pathophysiology of the disease. The participants answered questions related to the severity and impact of the signs and symptoms daily using a 11 point NRS with scores ranging from 0 (absent) to 10 (worst imaginable). Mean change in itch/pruritis NRS from Baseline to each study visit was presented. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the post dose weekly average value minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  10. Percentage of Participants Who Achieved a PGA Score of 0 or 1 and a Minimum 2 Grade Improvement From Baseline to Each Study Visit

    The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from baseline were summarized. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 16

  11. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. A TEAE is defined as an AE which occurred on or after study treatment start date and on or before the last visit. Number of participants with AEs and SAEs were presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.

    Time frame: Up to Week 16

  12. Number of Participants With Reported Local Tolerability Scores

    The assessment of the presence and degree of burning/stinging and itching at the application site following application of the study treatment was done at each specified study visit using a 5 point tolerability scale. The scores ranged from 0 to 4 where 0=None and 4=Strong/Severe. The score represented an average across all application sites. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 14

  13. Change From Baseline in Albumin and Protein Level

    Blood samples were collected for the evaluation of change in albumin and protein levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  14. Change From Baseline in Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Levels.

    Blood samples were collected for the evaluation of change in levels of alk phos, ALT, AST and GGT from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  15. Change From Baseline in Direct Bilirubin (Bil), Bilirubin (Bil), Creatinine and Urate.

    Blood samples were collected for the evaluation of change in levels of direct bil, bil, creatinine and urate from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  16. Change From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium and Urea Levels

    Blood samples were collected for the evaluation of change in levels of calcium, chloride, CO2, glucose, potassium, sodium, and urea from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  17. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocyte Count

    Blood samples were collected for the evaluation of change in levels of basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  18. Change From Baseline in Hematocrit Levels

    Blood samples were collected for the evaluation of change in hematocrit levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  19. Change From Baseline in Hemoglobin (Hgb) Level and Erythrocyte Mean Corpuscular Hgb Concentration (MCHC)

    Blood samples were collected for the evaluation of change in Hgb levels and MCHC from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  20. Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Level

    Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular hemoglobin level from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  21. Change From Baseline in Erythrocyte Mean Corpuscular Volume

    Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular volume from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  22. Change From Baseline in Erythrocyte Count

    Blood samples were collected for the evaluation of change in erythrocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  23. Number of Participants With Chemistry Data of Potential Clinical Importance

    Blood samples were collected for the evaluation of clinical chemistry parameters including alk phos, ALT, AST, bil, calcium, CO2, creatinine, glucose and potassium. The number of participants with chemistry data of potential clinical importance for the mentioned parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 14

  24. Number of Participants With Hematology Data of Clinical Importance

    Blood samples were collected for the evaluation of hematology parameters including hematocrit, Hgb, lymphocytes, neutrophils and platelets. The number of participants with clinically significant abnormal values of the mentioned hematology parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 14

  25. Change From Baseline in Immunoglobulin (Ig) A, IgG and IgM Levels

    Blood samples were collected for the evaluation of change in IgA, IgG and IgM levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 12

  26. Number of Participants With Ig Data Outside the Reference Range

    Blood samples were collected for the evaluation of change in Ig levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 12

  27. Number of Participants With Immunophenotyping Data Outside the Reference Range

    Blood samples were collected for the evaluation of change in levels of cluster of differentiation (CD)19, CD3, CD3 Treg flow cytometry (CD3TFLC), CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T Cell B Cell Natural Killer Lymphocytes flow cytometry (T-B cell NKL). Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 12

  28. Change From Baseline in Immunophenotype Data

    Blood samples were collected for the evaluation of change from Baseline in immunophenotype levels including CD19, CD3, CD3TFLC, CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T-B cell NKL. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 12

  29. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  30. Change From Baseline in Pulse Rate

    Pulse rate was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  31. Change From Baseline in Temperature

    Temperature was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline and up to Week 14

  32. Number of Participants With Vital Signs of Clinical Importance

    The vital signs including SBP, DBP and pulse rate were measured from Baseline throughout the study. The number of participants with clinically significant abnormal vital signs were presented. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 14

  33. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Single 12-lead ECGs were obtained over a brief recording period at each specified time point during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. For multiple ECGs at one visit, or "Any time post-screen", a participant is categorized as "Abnormal" if \>=1 assessment is abnormal. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Up to Week 14

07

Results

Posted Nov 13, 2017

Participant flow

This was a randomized, double-blind, dose-finding study of GSK2894512 in adult participants with psoriasis. The study consisted of 3 periods: 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of study for a participant was 16-20 weeks.

Participant flow — Overall Study
MilestoneGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Started383838383738
Completed273032352624
Not completed118631114
Withdrew: Adverse event443001
Withdrew: Lost to follow-up111011
Withdrew: Physician decision100100
Withdrew: Withdrawal by subject53221012

Outcome measures

PrimaryPercentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week 12

The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. The analysis was performed on modified intent-to-treat (mITT) Population which comprised of all randomized participants except those enrolled at center ID 220008.

Time frame:
Baseline and up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week 12
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Percentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week 1265564636115
Statistical analysis
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 54.7 · 95% CI 25.9 to 76.6Difference between GSK2894512 1% BID and Vehicle BID has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 51.0 · 95% CI 22.2 to 73.2Difference between GSK2894512 1% QD and Vehicle QD has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 35.6 · 95% CI 6.3 to 60.5Difference between GSK2894512 0.5% BID and Vehicle BID has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 30.7 · 95% CI 1.6 to 55.9Difference between GSK2894512 0.5% QD and Vehicle QD has been presented
SecondaryPercentage of Participants With >=75 Percent Improvement in Psoriasis Area and Severity Index (PASI) From Baseline to Each Study Visit

The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0 to 4) and the % BSA affected was scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. Higher scores indicated more severe disease. The percentage of participants with \>=75% improvement in PASI from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With >=75 Percent Improvement in Psoriasis Area and Severity Index (PASI) From Baseline to Each Study Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32030000
Week 2, n=32, 33, 30, 32, 24, 306153300
Week 4, n=28, 31, 29, 32, 22, 26322614650
Week 8, n=26, 27, 27, 32, 20, 205037373450
Week 12, n=23, 25, 26, 28, 19, 2065564646165
Week 14, n=23, 26, 24, 27, 19, 1965654648165
Week 16, n=24, 26, 26, 28, 19, 1963584654115
Early withdrawal (EW), n=10, 7, 4, 2, 10, 910430000
Statistical analysis
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 2.9 · 95% CI -21.0 to 26.6Difference between GSK2894512 1% QD and Vehicle QD at Week 1 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 6.3 · 95% CI -20.5 to 32.4Difference between GSK2894512 1% BID and Vehicle BID at Week 2 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 15.2 · 95% CI -9.6 to 39.1Difference between GSK2894512 1% QD and Vehicle QD at Week 2 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 3.3 · 95% CI -23.6 to 29.9Difference between GSK2894512 0.5% BID and Vehicle BID at Week 2 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 3.1 · 95% CI -22.2 to 28.1Difference between GSK2894512 0.5% QD and Vehicle QD at Week 2 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 27.6 · 95% CI -0.5 to 52.4Difference between GSK2894512 1% BID and Vehicle BID at Week 4 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 25.8 · 95% CI -0.4 to 49.3Difference between GSK2894512 1% QD and Vehicle QD at Week 4 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 9.2 · 95% CI -18.4 to 35.7Difference between GSK2894512 0.5% BID and Vehicle BID at Week 4 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 6.3 · 95% CI -19.7 to 31.7Difference between GSK2894512 0.5% QD and Vehicle QD at Week 4 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 45.0 · 95% CI 16.6 to 68.4Difference between GSK2894512 1% BID and Vehicle BID at Week 8 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 37.0 · 95% CI 8.7 to 61.3Difference between GSK2894512 1% QD and Vehicle QD at Week 8 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 32.0 · 95% CI 3.5 to 57.2Difference between GSK2894512 0.5% BID and Vehicle BID at Week 8 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 34.4 · 95% CI 6.3 to 58.7Difference between GSK2894512 0.5% QD and Vehicle QD at Week 8 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 49.4 · 95% CI 20.1 to 72.4Difference between GSK2894512 1% BID and Vehicle BID at Week 12 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 51.0 · 95% CI 22.2 to 73.2Difference between GSK2894512 1% QD and Vehicle QD at Week 12 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 30.4 · 95% CI 1.0 to 56.1Difference between GSK2894512 0.5% BID and Vehicle BID at Week 12 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 41.4 · 95% CI 12.7 to 65.0Difference between GSK2894512 0.5% QD and Vehicle QD at Week 12 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 49.4 · 95% CI 20.1 to 72.4Difference between GSK2894512 1% BID and Vehicle BID at Week 14 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 60.1 · 95% CI 33.2 to 80.1Difference between GSK2894512 1% QD and Vehicle QD at Week 14 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 30.0 · 95% CI 0.2 to 56.5Difference between GSK2894512 0.5% BID and Vehicle BID at Week 14 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 42.9 · 95% CI 14.4 to 66.5Difference between GSK2894512 0.5% QD and Vehicle QD at Week 14 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 52.0 · 95% CI 23.2 to 74.4Difference between GSK2894512 1% BID and Vehicle BID at Week 16 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 52.4 · 95% CI 24.4 to 74.0Difference between GSK2894512 1% QD and Vehicle QD at Week 16 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 35.6 · 95% CI 6.3 to 60.5Difference between GSK2894512 0.5% BID and Vehicle BID at Week 16 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 48.3 · 95% CI 19.7 to 71.1Difference between GSK2894512 0.5% QD and Vehicle QD at Week 16 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 10.0 · 95% CI -36.9 to 53.9Difference between GSK2894512 1% BID and Vehicle BID at EW has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 42.9 · 95% CI -6.3 to 81.6Difference between GSK2894512 1% QD and Vehicle QD at EW has been presented
SecondaryPercentage of Participants With a Minimum 2 Grade Improvement in PGA Score From Baseline to Each Study Visit

The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a minimum 2-grade improvement from Baseline for each study visit were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a Minimum 2 Grade Improvement in PGA Score From Baseline to Each Study Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32006040
Week 2, n=32, 33, 30, 32, 24, 30131213600
Week 4, n=28, 31, 29, 32, 22, 262123241350
Week 8, n=26, 27, 27, 32, 20, 204637414100
Week 12, n=23, 25, 26, 28, 19, 2065565036115
Week 14, n=23, 26, 24, 27, 19, 196162383750
Week 16, n=24, 26, 26, 28, 19, 195854383650
EW, n=10, 7, 4, 2, 10, 9204325000
SecondaryPercentage of Participants With a PGA Score of 0 or 1 at Each Study Visit

The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a PGA score of 0 or 1 from Baseline at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a PGA Score of 0 or 1 at Each Study Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32093040
Week 2, n=32, 33, 30, 32, 24, 30161810600
Week 4, n=28, 31, 29, 32, 22, 262142241654
Week 8, n=26, 27, 27, 32, 20, 205456444105
Week 12, n=23, 25, 26, 28, 19, 20707254391110
Week 14, n=23, 26, 24, 27, 19, 196169424155
Week 16, n=24, 26, 26, 28, 19, 195865504355
EW, n=10, 7, 4, 2, 10, 9105725000
SecondaryMean Change in Percent of BSA Affected With Psoriasis From Baseline to Each Study Visit

The extent of BSA affected by psoriasis is a general indicator of disease severity and was measured throughout the study. The extent of BSA to which study treatment was applied was also recorded. For the purpose of approximate clinical estimation, the total palmar surface of the palm plus 5 digits was assumed to be approximately equivalent to 1 percent BSA. Assessment of BSA affected with psoriasis was performed separately for four body surface regions: the head, the upper extremities, the trunk and the lower extremities, corresponding to 10, 20, 30 and 40 percent of the total body area, respectively. The mean change in percent BSA affected from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Mean · Percentage of BSA
Mean Change in Percent of BSA Affected With Psoriasis From Baseline to Each Study Visit
Percentage of BSAGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32-0.53 ± 1.136-0.30 ± 0.990-0.35 ± 0.7740.02 ± 0.773-0.05 ± 0.5100.01 ± 0.277
Week 2, n=32, 33, 30, 32, 24, 30-1.06 ± 1.496-0.75 ± 1.789-0.79 ± 1.350-0.51 ± 1.157-0.18 ± 0.657-0.13 ± 1.159
Week 4, n=28, 31, 29, 32, 22, 26-2.14 ± 3.275-2.13 ± 2.529-1.93 ± 2.951-0.80 ± 1.468-0.60 ± 1.332-0.17 ± 1.432
Week 8, n=26, 27, 27, 32, 20, 20-3.37 ± 3.590-3.60 ± 3.220-3.51 ± 3.756-1.77 ± 2.800-1.05 ± 1.823-0.65 ± 1.435
Week 12, n=23, 25, 26, 28, 19, 20-4.88 ± 4.211-4.28 ± 3.508-4.29 ± 3.882-3.59 ± 3.931-1.57 ± 2.380-0.98 ± 3.335
Week 14, n=23, 26, 24, 27, 19, 19-5.01 ± 4.108-4.63 ± 3.548-4.26 ± 4.172-3.59 ± 4.201-1.33 ± 2.475-0.58 ± 3.634
Week 16, n=24, 26, 26, 28, 19, 19-5.30 ± 4.468-4.47 ± 3.833-4.34 ± 4.299-3.56 ± 4.716-1.18 ± 2.490-1.10 ± 3.627
EW, n=10, 7, 4, 2, 10, 9-1.92 ± 2.218-2.31 ± 3.4650.25 ± 1.8931.25 ± 9.5460.74 ± 1.5361.17 ± 2.094
SecondaryMean Change in PASI Score From Baseline to Each Study Visit

The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of BSA affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0=None to 4=Severe) and the percent of BSA affected is scored on a 7-point scale (0=0% involvement to 6=90-100%) for each of 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. PASI score ranged from 0=no psoriasis to 72=worse psoriasis. The mean change in PASI score from Baseline was summarized for each study visit. Baseline was the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Mean · Scores on a scale
Mean Change in PASI Score From Baseline to Each Study Visit
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32-2.22 ± 2.795-1.73 ± 2.374-1.11 ± 2.083-1.33 ± 1.807-0.85 ± 1.203-0.28 ± 1.165
Week 2, n=32, 33, 30, 32, 24, 30-4.10 ± 3.756-3.07 ± 3.016-2.39 ± 3.118-2.49 ± 2.316-1.78 ± 2.826-0.61 ± 1.644
Week 4, n=28, 31, 29, 32, 22, 26-6.07 ± 5.051-4.45 ± 3.072-3.83 ± 3.827-3.31 ± 2.796-2.88 ± 3.308-1.08 ± 2.026
Week 8, n=26, 27, 27, 32, 20, 20-7.52 ± 5.612-5.77 ± 3.556-5.79 ± 5.055-4.58 ± 3.902-2.82 ± 4.081-1.34 ± 2.288
Week 12, n=23, 25, 26, 28, 19, 20-8.70 ± 5.617-6.62 ± 3.709-6.30 ± 5.138-5.41 ± 4.424-2.77 ± 4.291-1.54 ± 2.970
Week 14, n=23, 26, 24, 27, 19, 19-8.61 ± 5.328-6.65 ± 3.973-5.67 ± 5.100-5.28 ± 4.422-2.60 ± 4.491-1.29 ± 3.280
Week 16, n=24, 26, 26, 28, 19, 19-8.46 ± 5.432-6.63 ± 4.067-5.65 ± 5.646-5.13 ± 4.712-2.41 ± 4.285-1.09 ± 3.914
EW, n=10, 7, 4, 2, 10, 9-3.70 ± 3.391-4.00 ± 3.636-1.18 ± 1.1671.50 ± 8.627-0.06 ± 2.7840.12 ± 2.742
SecondaryPGA Scores at Each Study Visit

The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean of PGA scores at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 16
Reported as:
Mean · Scores on a scale
PGA Scores at Each Study Visit
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Baseline, n=34, 35, 32, 32, 30, 332.9 ± 0.422.7 ± 0.513.0 ± 0.542.9 ± 0.393.0 ± 0.262.8 ± 0.44
Week 1, n=32, 35, 31, 32, 28, 322.7 ± 0.592.4 ± 0.652.7 ± 0.652.6 ± 0.562.9 ± 0.522.8 ± 0.51
Week 2, n=32, 33, 30, 32, 24, 302.3 ± 0.772.2 ± 0.712.4 ± 0.672.5 ± 0.622.6 ± 0.502.6 ± 0.49
Week 4, n=28, 31, 29, 32, 22, 262.0 ± 0.671.6 ± 0.712.1 ± 0.772.1 ± 0.782.4 ± 0.592.6 ± 0.64
Week 8, n=26, 27, 27, 32, 20, 201.5 ± 0.861.4 ± 0.801.6 ± 0.751.7 ± 0.852.5 ± 0.512.5 ± 0.61
Week 12, n=23, 25, 26, 28, 19, 201.1 ± 0.921.1 ± 0.811.3 ± 1.011.6 ± 0.782.4 ± 0.692.5 ± 0.69
Week 14, n=23, 26, 24, 27, 19, 191.3 ± 1.011.1 ± 0.991.6 ± 0.881.7 ± 0.942.5 ± 0.612.5 ± 0.61
Week 16, n=24, 26, 26, 28, 19, 191.3 ± 1.081.2 ± 1.011.5 ± 0.901.7 ± 1.062.5 ± 0.612.6 ± 0.69
EW, n=10, 7, 4, 2, 10, 92.5 ± 1.081.6 ± 1.402.0 ± 1.412.5 ± 0.713.1 ± 0.573.1 ± 0.60
SecondaryMean Change in PGA Score From Baseline to Each Study Visit

The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean change in PGA scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Mean · Scores on a scale
Mean Change in PGA Score From Baseline to Each Study Visit
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32-0.3 ± 0.44-0.3 ± 0.48-0.3 ± 0.69-0.3 ± 0.47-0.1 ± 0.52-0.1 ± 0.30
Week 2, n=32, 33, 30, 32, 24, 30-0.7 ± 0.75-0.6 ± 0.70-0.6 ± 0.77-0.4 ± 0.62-0.4 ± 0.49-0.2 ± 0.50
Week 4, n=28, 31, 29, 32, 22, 26-1.0 ± 0.69-1.1 ± 0.70-0.9 ± 0.83-0.8 ± 0.78-0.5 ± 0.60-0.2 ± 0.51
Week 8, n=26, 27, 27, 32, 20, 20-1.4 ± 0.90-1.3 ± 0.88-1.4 ± 0.84-1.2 ± 0.97-0.5 ± 0.60-0.4 ± 0.49
Week 12, n=23, 25, 26, 28, 19, 20-1.8 ± 0.90-1.7 ± 1.03-1.7 ± 1.06-1.3 ± 0.81-0.5 ± 0.77-0.4 ± 0.67
Week 14, n=23, 26, 24, 27, 19, 19-1.7 ± 0.93-1.6 ± 1.20-1.4 ± 0.88-1.2 ± 0.92-0.5 ± 0.70-0.4 ± 0.50
Week 16, n=24, 26, 26, 28, 19, 19-1.6 ± 1.01-1.6 ± 1.24-1.4 ± 0.90-1.3 ± 1.00-0.4 ± 0.69-0.3 ± 0.56
EW, n=10, 7, 4, 2, 10, 9-0.5 ± 1.18-1.3 ± 1.38-1.0 ± 1.410.0 ± 1.410.0 ± 0.470.1 ± 0.60
SecondaryMean Change in Individual Target Lesion Grading Scores From Baseline to Each Study Visit

A single target lesion of at least 3 centimeter (cm) x 3 cm was selected at Baseline. For the selected lesion, the severity of erythema, scaling and plaque thickness (induration) was assessed by the investigator on a 5-point scale ranging from 0=none to 4=severe. The mean change in individual grading scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Mean · Scores on a scale
Mean Change in Individual Target Lesion Grading Scores From Baseline to Each Study Visit
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Scaling; Week 1, n=32, 35, 31, 32, 28, 32-0.7 ± 0.70-0.7 ± 0.90-0.4 ± 0.76-0.6 ± 0.56-0.5 ± 0.69-0.3 ± 0.44
Scaling; Week 2, n=32, 33, 30, 32, 24, 30-0.9 ± 0.78-1.0 ± 1.07-0.9 ± 0.87-1.0 ± 0.84-1.0 ± 0.75-0.3 ± 0.80
Scaling; Week 4, n=28, 31, 29, 32, 22, 26-1.5 ± 0.88-1.5 ± 1.21-1.4 ± 0.95-1.4 ± 0.98-1.0 ± 0.84-0.4 ± 0.80
Scaling; Week 8, n=26, 27, 27, 32, 20, 20-2.0 ± 1.11-2.0 ± 1.19-1.7 ± 1.07-1.9 ± 1.03-1.2 ± 0.93-0.4 ± 0.81
Scaling; Week 12, n=23, 25, 26, 29, 19, 20-2.3 ± 0.96-2.4 ± 1.15-2.1 ± 1.07-2.0 ± 1.05-1.0 ± 1.11-0.7 ± 0.81
Scaling; Week 14, n=23, 26, 24, 27, 19, 19-2.1 ± 1.20-2.2 ± 1.43-1.7 ± 1.17-1.8 ± 1.37-0.7 ± 1.05-0.5 ± 0.77
Scaling; Week 16, n=24, 26, 26, 28, 19, 19-2.1 ± 1.19-2.2 ± 1.24-1.6 ± 1.45-1.8 ± 1.29-0.6 ± 1.07-0.3 ± 0.67
Scaling; EW, n=10, 7, 4, 2, 10, 9-1.5 ± 1.27-1.6 ± 1.27-1.3 ± 1.50-0.5 ± 0.71-0.5 ± 0.970.0 ± 0.71
Erythema; Week 1, n=32, 35, 31, 32, 28, 32-0.4 ± 0.66-0.5 ± 0.78-0.3 ± 0.64-0.4 ± 0.50-0.2 ± 0.48-0.1 ± 0.39
Erythema; Week 2, n=32, 33, 30, 32, 24, 30-0.8 ± 0.83-1.1 ± 0.97-0.7 ± 0.94-0.8 ± 0.74-0.3 ± 0.75-0.2 ± 0.48
Erythema; Week 4, n=28, 31, 29, 32, 22, 26-1.3 ± 0.90-1.5 ± 0.89-1.3 ± 0.85-1.1 ± 0.80-0.6 ± 0.85-0.4 ± 0.64
Erythema; Week 8, n=26, 27, 27, 32, 20, 20-1.8 ± 1.10-2.0 ± 1.04-1.9 ± 0.95-1.5 ± 0.92-0.8 ± 0.85-0.5 ± 0.76
Erythema; Week 12, n=23, 25, 26, 29, 19, 20-2.3 ± 1.10-2.5 ± 1.08-2.2 ± 1.01-1.9 ± 1.13-0.5 ± 1.07-0.8 ± 0.97
Erythema; Week 14, n=23, 26, 24, 27, 19, 19-2.1 ± 1.28-2.2 ± 1.21-1.9 ± 0.95-1.7 ± 1.27-0.6 ± 1.12-0.9 ± 0.91
Erythema; Week 16, n=24, 26, 26, 28, 19, 19-2.1 ± 1.23-2.3 ± 1.09-1.8 ± 1.10-2.0 ± 1.26-0.6 ± 0.96-0.5 ± 0.90
Erythema; EW, n=10, 7, 4, 2, 10, 9-1.3 ± 1.06-1.4 ± 1.40-0.8 ± 1.500.0 ± 1.41-0.5 ± 0.97-0.1 ± 0.60
Plaque thickness; Week 1, n=32,35,31,32,28,32-0.5 ± 0.67-0.5 ± 0.82-0.4 ± 0.56-0.3 ± 0.60-0.4 ± 0.50-0.2 ± 0.45
Plaque thickness; Week 2, n=32,33,30,32,24,30-0.9 ± 0.84-0.9 ± 1.01-0.9 ± 0.94-0.8 ± 0.80-0.7 ± 0.76-0.3 ± 0.66
Plaque thickness; Week 4, n=28,31,29,32,22,26-1.4 ± 1.03-1.5 ± 1.26-1.3 ± 1.00-1.2 ± 0.93-1.0 ± 0.65-0.4 ± 0.64
Plaque thickness; Week 8, n=26,27,27,32,20,20-1.8 ± 1.17-1.8 ± 1.15-1.8 ± 1.09-1.7 ± 1.12-0.9 ± 0.88-0.5 ± 0.60
Plaque thickness; Week 12, n=23,25,26,29,19,20-2.3 ± 0.93-2.1 ± 1.19-1.9 ± 1.20-1.9 ± 1.13-1.0 ± 0.94-0.7 ± 0.80
Plaque thickness; Week 14, n=23,26,24,27,19,19-2.1 ± 1.16-2.1 ± 1.20-1.8 ± 1.19-1.7 ± 1.32-0.9 ± 1.13-0.7 ± 0.87
Plaque thickness; Week 16, n=24,26 26,28,19,19-2.1 ± 1.19-2.1 ± 1.32-1.6 ± 1.39-1.8 ± 1.31-0.7 ± 1.10-0.4 ± 0.69
Plaque thickness; EW, n=10,7,4,2,10,9-1.3 ± 1.06-1.9 ± 1.21-1.0 ± 1.410.0 ± 0.00-0.6 ± 1.070.4 ± 0.73
SecondaryMean Change in Weekly Average Itch/Pruritus Numeric Rating Scale (NRS) From Baseline to Each Study Visit

The participant reported itch severity was obtained from the response of the participants to the itch NRS item in the psoriasis symptom diary (PSD). PSD was developed to assess daily self-reports of psoriasis symptoms and the functional impact related to the underlying pathophysiology of the disease. The participants answered questions related to the severity and impact of the signs and symptoms daily using a 11 point NRS with scores ranging from 0 (absent) to 10 (worst imaginable). Mean change in itch/pruritis NRS from Baseline to each study visit was presented. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the post dose weekly average value minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Mean · Scores on a scale
Mean Change in Weekly Average Itch/Pruritus Numeric Rating Scale (NRS) From Baseline to Each Study Visit
Scores on a scaleGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=28, 33, 21, 31, 21, 29-0.66 ± 1.800-0.17 ± 2.007-1.00 ± 2.038-0.32 ± 1.710-1.31 ± 1.689-0.63 ± 1.612
Week 2, n=27, 30, 22, 32, 20, 25-1.62 ± 2.334-0.85 ± 1.870-1.97 ± 2.366-1.24 ± 1.949-1.66 ± 2.444-1.12 ± 2.147
Week 4, n=20, 25, 21, 30, 17, 24-2.35 ± 3.057-1.78 ± 2.402-3.13 ± 2.075-1.91 ± 2.723-1.67 ± 2.727-1.31 ± 2.338
Week 8, n=18, 22, 20, 29, 16, 20-3.66 ± 3.248-1.93 ± 2.543-3.29 ± 2.605-2.06 ± 2.842-1.98 ± 3.239-1.43 ± 2.664
Week 12, n=14, 20, 21, 24, 15, 18-3.53 ± 2.933-2.59 ± 2.923-3.65 ± 2.605-2.73 ± 2.922-2.46 ± 3.389-1.43 ± 2.765
Week 14, n=13, 14, 15, 24, 15, 13-3.56 ± 2.698-3.52 ± 2.489-3.58 ± 2.296-2.24 ± 3.067-1.90 ± 2.643-2.19 ± 2.898
Week 16, n=10, 9, 12, 19, 13, 10-3.67 ± 3.766-2.19 ± 2.695-3.66 ± 2.059-2.25 ± 2.992-2.36 ± 2.837-2.06 ± 3.225
EW, n=6, 3, 2, 0, 5, 5-1.77 ± 1.647-0.07 ± 1.501-5.67 ± 6.128—-1.79 ± 1.654-0.51 ± 1.391
SecondaryPercentage of Participants Who Achieved a PGA Score of 0 or 1 and a Minimum 2 Grade Improvement From Baseline to Each Study Visit

The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from baseline were summarized. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PGA Score of 0 or 1 and a Minimum 2 Grade Improvement From Baseline to Each Study Visit
Percentage of participantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=32, 35, 31, 32, 28, 32003040
Week 2, n=32, 33, 30, 32, 24, 309910600
Week 4, n=28, 31, 29, 32, 22, 261419171350
Week 8, n=26, 27, 27, 32, 20, 204237334100
Week 12, n=23, 25, 26, 28, 19, 2065564636115
Week 14, n=23, 26, 24, 27, 19, 195762293750
Week 16, n=24, 26, 26, 28, 19, 195854353650
EW, n=10, 7, 4, 2, 10, 9104325000
Statistical analysis
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: -3.6 · 95% CI -28.8 to 21.9Difference between GSK2894512 1% BID and Vehicle BID at Week 1 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: -0.3 · 95% CI -25.4 to 25.1Difference between GSK2894512 0.5% BID and Vehicle BID at Week 1 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 9.4 · 95% CI -17.5 to 35.3Difference between GSK2894512 1% BID and Vehicle BID at Week 2 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 9.1 · 95% CI -15.4 to 33.3Difference between GSK2894512 1% QD and Vehicle QD at Week 2 has been presented .
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 10.0 · 95% CI -17.1 to 36.1Difference between GSK2894512 0.5% BID and Vehicle BID at Week 2 has been presented .
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 6.3 · 95% CI -19.3 to 31.0Difference between GSK2894512 0.5% QD and Vehicle QD at Week 2 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 9.7 · 95% CI -18.2 to 36.7Difference between GSK2894512 1% BID and Vehicle BID at Week 4 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 19.4 · 95% CI -6.9 to 43.6Difference between GSK2894512 1% QD and Vehicle QD at Week 4 has been presented .
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 12.7 · 95% CI -15.1 to 38.9Difference between GSK2894512 0.5% BID and Vehicle BID at Week 4 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 12.5 · 95% CI -13.6 to 37.4Difference between GSK2894512 0.5% QD and Vehicle QD at Week 4 has been presented .
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 42.3 · 95% CI 13.8 to 66.0Difference between GSK2894512 1% BID and Vehicle BID at Week 8 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 37.0 · 95% CI 8.7 to 61.3Difference between GSK2894512 1% QD and Vehicle QD at Week 8 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 33.3 · 95% CI 4.8 to 58.2Difference between GSK2894512 0.5% BID and Vehicle BID at Week 8 has been presented .
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 40.6 · 95% CI 12.8 to 63.9Difference between GSK2894512 0.5% QD and Vehicle QD at Week 8 has been presented.
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 54.7 · 95% CI 25.9 to 76.6Difference between GSK2894512 1% BID and Vehicle BID at Week 12 has been presented.
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 51.0 · 95% CI 22.2 to 73.2Difference between GSK2894512 1% QD and Vehicle QD at Week 12 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 35.6 · 95% CI 6.3 to 60.5Difference between GSK2894512 0.5% BID and Vehicle BID at Week 12 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 30.7 · 95% CI 1.6 to 55.9Difference between GSK2894512 0.5% QD and Vehicle QD at Week 12 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 51.3 · 95% CI 22.0 to 74.0Difference between GSK2894512 1% BID and Vehicle BID at Week 14 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 61.5 · 95% CI 34.6 to 81.0Difference between GSK2894512 1% QD and Vehicle QD at Week 14 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 23.9 · 95% CI -6.1 to 51.0Difference between GSK2894512 0.5% BID and Vehicle BID at Week 14 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 37.0 · 95% CI 7.8 to 61.6Difference between GSK2894512 0.5% QD and Vehicle QD at Week 14 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 53.1 · 95% CI 24.7 to 75.6Difference between GSK2894512 1% BID and Vehicle BID at Week 16 has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 53.8 · 95% CI 25.8 to 75.5Difference between GSK2894512 1% QD and Vehicle QD at Week 16 has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 29.4 · 95% CI -0.3 to 55.0Difference between GSK2894512 0.5% BID and Vehicle BID at Week 16 has been presented
  • GSK2894512 0.5% QD vs Vehicle QD · Proportion difference: 35.7 · 95% CI 6.5 to 60.2Difference between GSK2894512 0.5% QD and Vehicle QD at Week 16 has been presented
  • GSK2894512 1% BID vs Vehicle BID · Proportion difference: 10.0 · 95% CI -36.9 to 53.9Difference between GSK2894512 1% BID and Vehicle BID at EW has been presented
  • GSK2894512 1% QD vs Vehicle QD · Proportion difference: 42.9 · 95% CI -6.3 to 81.6Difference between GSK2894512 1% QD and Vehicle QD at EW has been presented
  • GSK2894512 0.5% BID vs Vehicle BID · Proportion difference: 25.0 · 95% CI -35.7 to 80.6Difference between GSK2894512 0.5% BID and Vehicle BID at EW has been presented
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. A TEAE is defined as an AE which occurred on or after study treatment start date and on or before the last visit. Number of participants with AEs and SAEs were presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.

Time frame:
Up to Week 16
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
TEAEs26202217910
serious TEAEs133000
SecondaryNumber of Participants With Reported Local Tolerability Scores

The assessment of the presence and degree of burning/stinging and itching at the application site following application of the study treatment was done at each specified study visit using a 5 point tolerability scale. The scores ranged from 0 to 4 where 0=None and 4=Strong/Severe. The score represented an average across all application sites. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 14
Reported as:
Number · Participants
Number of Participants With Reported Local Tolerability Scores
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, none, n=36, 38, 37,38, 35, 37191718261926
Week 1, slight, n=36, 38, 37,38, 35, 37487168
Week 1, mild, n=36, 38, 37,38, 35, 37895862
Week 1, moderate, n=36, 38, 37,38, 35, 37446321
Week 1, strong/severe, n=36, 38, 37,38, 35, 37101020
Week 2, none, n=36, 36, 36,38, 31, 35242820312326
Week 2, slight, n=36, 36, 36,38, 31, 35447445
Week 2, mild, n=36, 36, 36,38, 31, 35743214
Week 2, moderate, n=36, 36, 36,38, 31, 35106110
Week 2, strong/severe, n=36, 36, 36,38, 31, 35000020
Week 4, none, n=32, 34, 35,38, 29, 31192423322126
Week 4, slight, n=32, 34, 35,38, 29, 31754233
Week 4, mild, n=32, 34, 35,38, 29, 31445331
Week 4, moderate, n=32, 34, 35,38, 29, 31213111
Week 4, strong/severe, n=32, 34, 35,38, 29, 31000010
Week 8, none, n=30, 31, 33,38, 27, 26242424332422
Week 8, slight, n=30, 31, 33,38, 27, 26475332
Week 8, mild, n=30, 31, 33,38, 27, 26103100
Week 8, moderate, n=30, 31, 33,38, 27, 26101102
Week 8, strong/severe, n=30, 31, 33,38, 27, 26000000
Week 12, none, n=27, 29, 32,35, 26, 25202425312423
Week 12, slight, n=27, 29, 32,35, 26, 25423321
Week 12, mild, n=27, 29, 32,35, 26, 25233100
Week 12, moderate, n=27, 29, 32,35, 26, 25101001
Week 12, strong/severe, n=27, 29, 32,35, 26, 25000000
Week 14, none, n=27, 30, 33, 33, 27, 24242525312523
Week 14, slight, n=27, 30, 33, 33, 27, 24133210
Week 14, mild, n=27, 30, 33, 33, 27, 24113010
Week 14, moderate, n=27, 30, 33, 33, 27, 24112001
Week 14, strong/severe, n=27, 30, 33, 33, 27, 24000000
EW, none, n=9, 7, 4, 2, 10, 9420248
EW, slight, n=9, 7, 4, 2, 10, 9121020
EW, mild, n=9, 7, 4, 2, 10, 9002020
EW, moderate, n=9, 7, 4, 2, 10, 9210011
EW, strong/severe, n=9,7,4, 2, 10, 9221010
SecondaryChange From Baseline in Albumin and Protein Level

Blood samples were collected for the evaluation of change in albumin and protein levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · grams/liter (g/L)
Change From Baseline in Albumin and Protein Level
grams/liter (g/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Albumin, Week 2, n=35, 36, 35, 37, 29, 34-0.9 ± 2.11-1.1 ± 2.70-0.9 ± 2.83-1.1 ± 2.33-0.9 ± 3.37-0.6 ± 2.76
Albumin, Week 4, n=32, 34, 33, 37, 29, 30-1.3 ± 2.10-1.2 ± 2.52-1.0 ± 3.57-0.4 ± 1.99-0.8 ± 3.53-0.2 ± 3.23
Albumin, Week 8, n=30, 31, 32, 37, 27, 26-1.0 ± 1.65-0.6 ± 2.33-1.0 ± 3.33-1.0 ± 2.49-0.6 ± 3.19-1.0 ± 2.36
Albumin, Week 12, n=27, 30, 32, 36, 26, 24-0.8 ± 2.19-0.5 ± 3.31-1.3 ± 3.39-1.2 ± 1.67-0.6 ± 3.14-1.1 ± 2.85
Albumin, Week 14, n=29, 31, 33, 34, 27, 24-1.3 ± 2.74-1.1 ± 2.72-1.5 ± 2.71-1.1 ± 2.81-1.6 ± 4.24-2.0 ± 2.40
Albumin, EW, n=10, 6, 3, 2, 10, 9-0.3 ± 2.06-1.7 ± 2.500.0 ± 3.46-3.5 ± 3.54-0.8 ± 1.99-0.2 ± 2.54
Protein, Week 2, n=35, 36, 35, 37, 29, 34-1.1 ± 3.84-2.5 ± 3.95-1.3 ± 4.25-1.5 ± 3.07-1.8 ± 4.21-1.0 ± 4.25
Protein, Week 4, n=32, 34, 33, 37, 29, 30-2.3 ± 3.23-2.9 ± 3.41-0.9 ± 4.94-0.7 ± 3.37-1.9 ± 4.99-0.3 ± 4.70
Protein, Week 8, n=30, 31, 32, 37, 27, 26-2.1 ± 3.28-1.7 ± 3.74-1.9 ± 4.88-1.3 ± 3.89-1.5 ± 4.42-1.4 ± 3.30
Protein, Week 12, n=27, 30, 32, 36, 26, 24-1.3 ± 2.73-2.5 ± 3.72-2.4 ± 4.23-1.7 ± 3.27-1.8 ± 4.05-1.5 ± 3.84
Protein, Week 14, n=29, 31, 33, 34, 27, 24-2.1 ± 3.06-2.9 ± 3.61-2.4 ± 4.34-1.9 ± 4.01-3.0 ± 4.32-2.6 ± 2.81
Protein, EW, n=10, 6, 3, 2, 10, 9-0.8 ± 2.66-3.5 ± 3.83-3.0 ± 5.00-3.5 ± 2.12-1.2 ± 3.52-0.2 ± 3.42
SecondaryChange From Baseline in Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Levels.

Blood samples were collected for the evaluation of change in levels of alk phos, ALT, AST and GGT from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · International Units (IU)/L
Change From Baseline in Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Levels.
International Units (IU)/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Alk. Phos, Week 2, n=35, 36, 35, 37, 29, 34-0.6 ± 10.83-0.9 ± 8.44-0.7 ± 13.47-2.9 ± 10.930.7 ± 18.06-2.1 ± 7.02
Alk. Phos, Week 4, n=32, 34, 33, 37, 29, 30-0.2 ± 20.50-0.6 ± 7.030.1 ± 13.510.4 ± 11.33-0.0 ± 14.42-2.9 ± 8.69
Alk. Phos, Week 8, n=30, 31, 32, 37, 27, 26-4.1 ± 17.59-1.2 ± 11.06-0.1 ± 9.53-3.9 ± 9.540.0 ± 12.562.3 ± 11.25
Alk. Phos, Week 12, n=27, 30, 32, 36, 26, 24-5.7 ± 18.74-3.1 ± 10.45-1.7 ± 9.29-2.3 ± 8.30-1.7 ± 15.721.2 ± 13.29
Alk. Phos, Week 14, n=29, 31, 33, 34, 27, 24-2.3 ± 15.62-4.1 ± 10.56-3.1 ± 12.34-4.9 ± 13.20-2.4 ± 16.98-2.8 ± 13.62
Alk. Phos, EW, n=10, 6, 3, 2, 10, 9-3.7 ± 7.272.7 ± 10.957.7 ± 16.80-13.5 ± 6.36-3.4 ± 10.51-1.8 ± 9.13
ALT, Week 2, n=35, 36, 35, 37, 29, 34-2.1 ± 7.98-2.6 ± 7.95-2.3 ± 6.18-2.9 ± 9.75-2.7 ± 13.45-1.3 ± 4.54
ALT, Week 4, n=32, 34, 33, 37, 29, 300.3 ± 22.68-2.7 ± 5.99-3.7 ± 13.21-2.9 ± 9.91-2.4 ± 11.832.3 ± 9.10
ALT, Week 8, n=30, 31, 32, 37, 27, 26-1.5 ± 10.37-3.9 ± 12.470.1 ± 11.68-4.4 ± 10.880.3 ± 14.28-0.4 ± 10.21
ALT, Week 12, n=27, 30, 32, 36, 26, 24-1.8 ± 15.35-2.2 ± 8.25-0.1 ± 13.72-5.4 ± 9.54-2.6 ± 14.931.5 ± 20.39
ALT, Week 14, n=29, 31, 33, 34, 27, 24-3.8 ± 17.42-3.5 ± 10.37-1.8 ± 12.99-6.5 ± 10.33-1.4 ± 19.63-1.7 ± 9.27
ALT, EW, n=10, 6, 3, 2, 10, 9-1.1 ± 5.02-2.2 ± 7.315.0 ± 16.64-5.0 ± 7.07-8.2 ± 12.16-1.3 ± 5.52
AST, Week 2, n=35, 36, 35, 37, 29, 34-0.6 ± 4.91-1.2 ± 5.090.5 ± 3.71-1.8 ± 11.91-2.3 ± 10.76-1.0 ± 5.70
AST, Week 4, n=32, 34, 33, 37, 29, 300.2 ± 9.76-1.9 ± 3.21-1.0 ± 5.22-3.1 ± 11.61-1.9 ± 9.050.5 ± 6.66
AST, Week 8, n=30, 31, 32, 37, 27, 26-1.0 ± 4.22-2.2 ± 6.322.6 ± 11.60-4.2 ± 11.50-0.3 ± 10.52-1.7 ± 8.47
AST, Week 12, n=27, 30, 32, 36, 26, 240.6 ± 9.09-2.2 ± 7.491.9 ± 8.89-4.1 ± 9.90-1.6 ± 12.75-0.3 ± 8.45
AST, Week 14, n=29, 31, 33, 34, 27, 24-0.4 ± 7.55-2.7 ± 8.760.7 ± 8.39-5.1 ± 11.36-1.3 ± 13.40-1.0 ± 6.92
AST, EW, n=10, 6, 3, 2, 10, 9-1.0 ± 4.245.2 ± 15.841.7 ± 9.07-1.0 ± 4.24-3.7 ± 7.73-0.3 ± 7.48
GGT, Week 2, n=35, 36, 35, 37, 29, 34-1.0 ± 6.63-2.1 ± 8.38-0.4 ± 17.64-1.6 ± 14.39-3.1 ± 15.17-4.5 ± 9.92
GGT, Week 4, n=32, 34, 33, 37, 29, 308.5 ± 56.71-3.5 ± 17.84-4.6 ± 22.060.3 ± 15.40-2.5 ± 18.08-2.1 ± 11.77
GGT, Week 8, n=30, 31, 32, 37, 27, 261.9 ± 20.56-7.6 ± 32.91-1.2 ± 21.11-3.2 ± 20.11-3.1 ± 23.93-0.4 ± 13.61
GGT, Week 12, n=27, 30, 32, 36, 26, 24-0.1 ± 24.48-2.4 ± 12.782.1 ± 20.03-5.9 ± 12.56-3.7 ± 30.643.3 ± 23.10
GGT, Week 14, n=29, 31, 33, 34, 27, 24-1.9 ± 16.31-2.5 ± 11.69-0.1 ± 16.58-5.9 ± 17.67-0.5 ± 38.93-1.3 ± 11.15
GGT, EW, n=10, 6, 3, 2, 10, 9-2.0 ± 6.25-5.3 ± 7.42-2.0 ± 6.56-2.5 ± 7.78-2.6 ± 4.65-10.1 ± 25.73
SecondaryChange From Baseline in Direct Bilirubin (Bil), Bilirubin (Bil), Creatinine and Urate.

Blood samples were collected for the evaluation of change in levels of direct bil, bil, creatinine and urate from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · micromoles (µmol)/L
Change From Baseline in Direct Bilirubin (Bil), Bilirubin (Bil), Creatinine and Urate.
micromoles (µmol)/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Direct bil, Week 2, n=35, 36, 35, 37, 29, 34-0.2 ± 0.81-0.4 ± 1.360.0 ± 1.08-0.1 ± 1.24-0.1 ± 1.510.0 ± 0.85
Direct bil, Week 4, n=32, 34, 33, 37, 29, 30-0.3 ± 0.67-0.5 ± 1.50-0.1 ± 1.17-0.2 ± 0.99-0.1 ± 1.36-0.1 ± 1.17
Direct bil, Week 8, n=30, 31, 32, 37, 27, 26-0.4 ± 0.97-0.3 ± 1.24-0.2 ± 0.93-0.2 ± 1.03-0.1 ± 1.35-0.5 ± 1.33
Direct bil, Week 12, n=27, 30, 32, 36, 26, 24-0.2 ± 0.64-0.3 ± 1.26-0.2 ± 1.18-0.4 ± 1.150.0 ± 1.26-0.1 ± 1.10
Direct bil, Week 14, n=29, 31, 33, 34, 27, 240.1 ± 1.19-0.3 ± 1.28-0.1 ± 1.06-0.1 ± 1.040.1 ± 1.52-0.2 ± 0.82
Direct bil, EW, n=10, 6, 3, 2, 10, 90.2 ± 1.140.0 ± 0.000.0 ± 0.002.0 ± 0.00-0.4 ± 1.26-0.2 ± 1.20
Bil, Week 2, n=35, 36, 35, 37, 29, 34-0.7 ± 3.03-1.4 ± 3.24-0.6 ± 2.98-0.3 ± 2.56-0.3 ± 4.400.8 ± 4.15
Bil, Week 4, n=32, 34, 33, 37, 29, 30-0.4 ± 3.50-1.2 ± 3.420.4 ± 4.34-0.6 ± 2.87-0.6 ± 4.841.7 ± 4.29
Bil, Week 8, n=30, 31, 32, 37, 27, 26-0.3 ± 2.860.1 ± 2.73-0.8 ± 2.48-0.3 ± 3.06-0.9 ± 4.270.2 ± 3.81
Bil, Week 12, n=27, 30, 32, 36, 26, 24-0.2 ± 2.10-0.7 ± 2.70-0.9 ± 3.13-0.4 ± 3.13-0.4 ± 4.930.6 ± 4.02
Bil, Week 14, n=29, 31, 33, 34, 27, 240.6 ± 3.70-0.7 ± 4.34-0.9 ± 2.74-0.5 ± 3.56-0.8 ± 4.840.5 ± 2.96
Bil, EW, n=10, 6, 3, 2, 10, 9-0.8 ± 2.530.0 ± 2.192.7 ± 3.06-1.0 ± 1.410.4 ± 3.10-0.2 ± 3.23
Creatinine, Week 2, n=35, 36, 35, 37, 29, 34-0.26 ± 7.5650.86 ± 9.5881.14 ± 7.2020.27 ± 9.708-1.65 ± 5.8121.22 ± 6.632
Creatinine, Week 4, n=32, 34, 33, 37, 29, 30-2.27 ± 6.4930.12 ± 8.4690.97 ± 7.8021.81 ± 7.510-2.38 ± 6.0951.57 ± 10.282
Creatinine, Week 8, n=30, 31, 32, 37, 27, 26-0.09 ± 6.7920.55 ± 7.0300.48 ± 7.0862.82 ± 11.713-2.89 ± 7.5661.40 ± 8.515
Creatinine, Week 12, n=27, 30, 32, 36, 26, 242.39 ± 7.5260.14 ± 6.5430.34 ± 6.8520.37 ± 11.501-4.35 ± 10.5281.49 ± 7.718
Creatinine, Week 14, n=29, 31, 33, 34, 27, 241.74 ± 5.7481.67 ± 7.3163.41 ± 7.3091.67 ± 14.096-2.33 ± 9.7153.06 ± 8.970
Creatinine, EW, n=10, 6, 3, 2, 10, 9-0.80 ± 8.570-5.02 ± 9.37421.77 ± 31.832-1.80 ± 0.000-1.58 ± 6.009-2.36 ± 5.544
Urate, Week 2, n=35, 36, 35, 37, 29, 34-6.0 ± 55.26-7.8 ± 40.2915.4 ± 41.966.2 ± 61.07-8.3 ± 62.91-0.3 ± 62.06
Urate, Week 4, n=32, 34, 33, 37, 29, 30-12.5 ± 34.36-7.9 ± 43.8211.2 ± 48.015.7 ± 49.36-10.7 ± 54.112.7 ± 52.06
Urate, Week 8, n=30, 31, 32, 37, 27, 26-5.0 ± 37.30-8.7 ± 37.13-3.8 ± 32.30-0.3 ± 45.43-6.3 ± 73.54-4.2 ± 75.80
Urate, Week 12, n=27, 30, 32, 36, 26, 24-6.3 ± 28.445.7 ± 34.511.6 ± 35.21-1.7 ± 55.010.4 ± 88.7915.4 ± 66.27
Urate, Week 14, n=29, 31, 33, 34, 27, 243.1 ± 41.1519.4 ± 71.0416.4 ± 48.98-5.9 ± 54.72-14.1 ± 59.37-2.5 ± 65.62
Urate, EW, n=10, 6, 3, 2, 10, 9-2.0 ± 35.21-38.3 ± 31.8976.7 ± 98.15-10.0 ± 14.14-13.0 ± 33.68-13.3 ± 52.92
SecondaryChange From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium and Urea Levels

Blood samples were collected for the evaluation of change in levels of calcium, chloride, CO2, glucose, potassium, sodium, and urea from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · millimoles (mmol)/L
Change From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium and Urea Levels
millimoles (mmol)/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Calcium, Week 2, n=35, 36, 35, 37, 29, 34-0.036 ± 0.1241-0.036 ± 0.0935-0.041 ± 0.1411-0.036 ± 0.0967-0.048 ± 0.1239-0.006 ± 0.0887
Calcium, Week 4, n=32, 34, 33, 37, 29, 30-0.037 ± 0.1003-0.045 ± 0.0788-0.033 ± 0.1306-0.014 ± 0.0899-0.036 ± 0.14510.003 ± 0.0830
Calcium, Week 8, n=30, 31, 32, 37, 27, 26-0.034 ± 0.1205-0.015 ± 0.0853-0.036 ± 0.0951-0.010 ± 0.1000-0.039 ± 0.1131-0.017 ± 0.0948
Calcium, Week 12, n=27, 30, 32, 36, 26, 24-0.019 ± 0.0910-0.013 ± 0.0934-0.034 ± 0.0845-0.021 ± 0.1129-0.032 ± 0.09880.011 ± 0.1127
Calcium, Week 14, n=29, 31, 33, 34, 27, 24-0.028 ± 0.0912-0.030 ± 0.1067-0.029 ± 0.0930-0.025 ± 0.0935-0.045 ± 0.1270-0.020 ± 0.1052
Calcium, EW, n=10, 6, 3, 2, 10, 9-0.024 ± 0.0717-0.020 ± 0.06320.007 ± 0.1286-0.030 ± 0.0990-0.014 ± 0.03660.004 ± 0.0691
Chloride, Week 2, n=35, 36, 35, 37, 29, 34-0.1 ± 2.300.3 ± 2.00-0.3 ± 1.980.1 ± 2.050.3 ± 2.44-0.0 ± 2.29
Chloride, Week 4, n=32, 34, 33, 37, 29, 30-0.1 ± 1.660.5 ± 1.97-0.4 ± 2.56-0.5 ± 1.830.1 ± 2.62-0.7 ± 2.74
Chloride, Week 8, n=30, 31, 32, 37, 27, 260.3 ± 1.730.6 ± 1.89-0.3 ± 2.020.3 ± 2.03-0.1 ± 2.13-0.3 ± 3.07
Chloride, Week 12, n=27, 30, 32, 36, 26, 24-0.4 ± 2.620.7 ± 2.000.1 ± 2.29-0.2 ± 2.350.7 ± 2.37-0.7 ± 2.80
Chloride, Week 14, n=29, 31, 33, 34, 27, 240.4 ± 2.240.5 ± 2.23-0.3 ± 2.310.5 ± 2.30-0.3 ± 2.840.2 ± 2.55
Chloride, EW, n=10, 6, 3, 2, 10, 9-0.8 ± 3.19-1.5 ± 0.84-1.0 ± 2.001.0 ± 1.410.0 ± 2.31-1.9 ± 2.98
CO2, Week 2, n=35, 36, 35, 37, 29, 34-1.6 ± 2.13-1.1 ± 2.48-1.2 ± 2.64-1.2 ± 1.96-0.6 ± 2.37-0.9 ± 2.04
CO2, Week 4, n=32, 34, 33, 37, 29, 30-1.0 ± 2.21-1.4 ± 2.57-2.0 ± 2.81-0.8 ± 2.12-0.5 ± 1.99-1.5 ± 2.50
CO2, Week 8, n=30, 31, 32, 37, 27, 26-1.6 ± 2.19-1.5 ± 2.49-1.3 ± 1.89-1.0 ± 2.25-1.0 ± 1.85-1.5 ± 2.47
CO2, Week 12, n=27, 30, 32, 36, 26, 24-1.0 ± 1.58-1.1 ± 1.87-1.2 ± 2.55-1.1 ± 2.31-0.9 ± 2.66-1.1 ± 2.23
CO2, Week 14, n=29, 31, 33, 34, 27, 24-0.7 ± 2.02-0.7 ± 2.55-1.0 ± 2.38-1.1 ± 2.32-0.3 ± 2.31-1.2 ± 2.19
CO2, EW, n=10, 6, 3, 2, 10, 9-1.7 ± 1.570.5 ± 1.520.0 ± 3.460.0 ± 1.41-0.6 ± 1.65-0.1 ± 1.27
Glucose, Week 2, n=35, 36, 35, 37, 29, 340.35 ± 1.1470.59 ± 1.445-0.09 ± 1.8520.05 ± 1.864-0.01 ± 1.1680.28 ± 1.398
Glucose, Week 4, n=32, 34, 33, 37, 29, 300.84 ± 1.7500.53 ± 1.6560.40 ± 3.0590.42 ± 2.8420.01 ± 1.2990.73 ± 2.436
Glucose, Week 8, n=30, 31, 32, 37, 27, 260.32 ± 1.5710.29 ± 1.3400.63 ± 2.6040.35 ± 1.3760.18 ± 1.5050.55 ± 2.392
Glucose, Week 12, n=27, 30, 32, 36, 26, 240.26 ± 2.223-0.33 ± 1.0990.42 ± 2.704-0.02 ± 1.977-0.24 ± 0.9660.45 ± 1.703
Glucose, Week 14, n=29, 31, 33, 34, 27, 240.03 ± 1.7080.15 ± 1.6280.79 ± 2.6080.12 ± 2.224-0.02 ± 2.1040.13 ± 1.696
Glucose, EW, n=10, 6, 3, 2, 10, 90.00 ± 1.5240.58 ± 2.1850.43 ± 1.361-0.25 ± 0.2120.35 ± 0.3570.37 ± 1.665
Potassium, Week 2, n=35, 36, 35, 37, 29, 340.07 ± 0.4120.03 ± 0.3220.10 ± 0.4500.12 ± 0.3490.20 ± 0.408-0.00 ± 0.306
Potassium, Week 4, n=32, 34, 33, 37, 29, 300.07 ± 0.3820.09 ± 0.3700.05 ± 0.281-0.01 ± 0.3070.13 ± 0.4800.01 ± 0.380
Potassium, Week 8, n=30, 31, 32, 37, 27, 260.10 ± 0.3650.09 ± 0.5760.06 ± 0.312-0.04 ± 0.3020.05 ± 0.3770.10 ± 0.600
Potassium, Week 12, n=27, 30, 32, 36, 26, 24-0.07 ± 0.3210.02 ± 0.2280.13 ± 0.3950.00 ± 0.3590.02 ± 0.3760.02 ± 0.298
Potassium, Week 14, n=29, 31, 33, 34, 27, 24-0.01 ± 0.2740.02 ± 0.2680.05 ± 0.361-0.06 ± 0.319-0.01 ± 0.3720.01 ± 0.372
Potassium, EW, n=10, 6, 3, 2, 10, 9-0.05 ± 0.217-0.02 ± 0.6050.23 ± 0.4930.35 ± 0.071-0.15 ± 0.357-0.08 ± 0.291
Sodium, Week 2, n=35, 36, 35, 37, 29, 34-0.7 ± 2.19-0.2 ± 2.04-0.2 ± 2.13-0.6 ± 2.09-0.0 ± 2.21-0.5 ± 1.94
Sodium, Week 4, n=32, 34, 33, 37, 29, 30-0.6 ± 1.52-0.1 ± 1.81-1.1 ± 2.28-0.8 ± 2.070.1 ± 2.47-1.2 ± 2.06
Sodium, Week 8, n=30, 31, 32, 37, 27, 26-0.3 ± 1.86-0.2 ± 1.93-0.9 ± 2.01-0.2 ± 2.25-1.1 ± 2.21-0.8 ± 2.43
Sodium, Week 12, n=27, 30, 32, 36, 26, 24-0.6 ± 2.750.1 ± 1.93-0.3 ± 2.43-0.5 ± 1.90-0.2 ± 2.60-1.2 ± 2.08
Sodium, Week 14, n=29, 31, 33, 34, 27, 24-0.3 ± 2.17-0.2 ± 1.51-0.6 ± 2.18-0.7 ± 2.29-0.8 ± 2.33-1.0 ± 2.30
Sodium, EW, n=10, 6, 3, 2, 10, 9-1.4 ± 2.17-0.5 ± 1.52-1.0 ± 2.651.0 ± 1.41-0.8 ± 2.15-2.0 ± 2.06
Urea, Week 2, n=35, 36, 35, 37, 29, 340.17 ± 1.3170.44 ± 2.2420.06 ± 1.1930.38 ± 1.187-0.09 ± 1.0440.10 ± 1.347
Urea, Week 4, n=32, 34, 33, 37, 29, 30-0.23 ± 0.9070.41 ± 1.4690.05 ± 1.1950.36 ± 0.991-0.19 ± 1.1980.28 ± 1.501
Urea, Week 8, n=30, 31, 32, 37, 27, 26-0.07 ± 1.158-0.13 ± 1.049-0.45 ± 1.3100.32 ± 0.876-0.22 ± 1.022-0.13 ± 1.179
Urea, Week 12, n=27, 30, 32, 36, 26, 24-0.17 ± 0.8880.28 ± 1.201-0.27 ± 1.3440.43 ± 1.220-0.19 ± 0.861-0.15 ± 1.485
Urea, Week 14, n=29, 31, 33, 34, 27, 24-0.10 ± 1.1050.55 ± 1.485-0.08 ± 1.4420.07 ± 1.3030.35 ± 1.199-0.15 ± 1.272
Urea, EW, n=10, 6, 3, 2, 10, 90.25 ± 1.007-0.83 ± 0.9831.83 ± 3.8840.00 ± 1.414-0.05 ± 1.0120.28 ± 1.460
SecondaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocyte Count

Blood samples were collected for the evaluation of change in levels of basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · Giga unit/liter (GI/L)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocyte Count
Giga unit/liter (GI/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Basophils, Week 2, n=35, 35, 36, 37, 29, 350.004 ± 0.0213-0.005 ± 0.0167-0.005 ± 0.01780.006 ± 0.02430.003 ± 0.02480.003 ± 0.0172
Basophils, Week 4, n=31, 34, 35, 37, 29, 310.003 ± 0.0176-0.002 ± 0.0285-0.002 ± 0.0166-0.003 ± 0.01840.002 ± 0.0175-0.000 ± 0.0143
Basophils, Week 8, n=30, 30, 32, 37, 27, 26-0.001 ± 0.0167-0.001 ± 0.0181-0.004 ± 0.0150-0.002 ± 0.01950.002 ± 0.0233-0.008 ± 0.0145
Basophils, Week 12, n=27, 30, 31, 36, 26, 25-0.003 ± 0.01510.004 ± 0.0233-0.007 ± 0.01700.000 ± 0.01610.006 ± 0.0250-0.003 ± 0.0151
Basophils, Week 14, n=29, 30, 33, 34, 27, 23-0.003 ± 0.0176-0.003 ± 0.0184-0.003 ± 0.01880.002 ± 0.0250-0.001 ± 0.0188-0.001 ± 0.0216
Basophils, EW, n=10, 6, 3, 2, 10, 9-0.001 ± 0.0179-0.017 ± 0.0294-0.010 ± 0.01000.000 ± 0.000-0.005 ± 0.01510.012 ± 0.0217
Eosinophils, Week 2, n=35, 35, 36, 37, 29, 350.021 ± 0.11570.043 ± 0.1356-0.017 ± 0.18570.011 ± 0.0972-0.021 ± 0.1363-0.015 ± 0.1295
Eosinophils, Week 4, n=31, 34, 35, 37, 29, 310.019 ± 0.13800.034 ± 0.1371-0.005 ± 0.15540.005 ± 0.0954-0.019 ± 0.1205-0.005 ± 0.1522
Eosinophils, Week 8, n=30, 30, 32, 37, 27, 260.012 ± 0.11340.024 ± 0.1015-0.008 ± 0.14950.037 ± 0.1001-0.008 ± 0.1142-0.048 ± 0.1258
Eosinophils, Week 12, n=27, 30, 31, 36, 26, 250.047 ± 0.23020.000 ± 0.1002-0.032 ± 0.17140.026 ± 0.09340.001 ± 0.1375-0.027 ± 0.1322
Eosinophils, Week 14, n=29, 30, 33, 34, 27, 230.033 ± 0.10840.004 ± 0.0979-0.011 ± 0.21860.002 ± 0.10530.004 ± 0.1469-0.053 ± 0.1867
Eosinophils, EW, n=10, 6, 3, 2, 10, 90.029 ± 0.08410.090 ± 0.1563-0.233 ± 0.39550.095 ± 0.00710.053 ± 0.2675-0.047 ± 0.1775
Lymphocytes, Week 2, n=35, 35, 36, 37, 29, 350.100 ± 0.4690-0.002 ± 0.38270.097 ± 0.39950.145 ± 0.3966-0.138 ± 0.4764-0.018 ± 0.4774
Lymphocytes, Week 4, n=31, 34, 35, 37, 29, 31-0.083 ± 0.6201-0.044 ± 0.41010.041 ± 0.38750.228 ± 0.5664-0.142 ± 0.4421-0.077 ± 0.4524
Lymphocytes, Week 8, n=30, 30, 32, 37, 27, 260.048 ± 0.5656-0.009 ± 0.3778-0.048 ± 0.43790.075 ± 0.5255-0.110 ± 0.64060.032 ± 0.4913
Lymphocytes, Week 12, n=27, 30, 31, 36, 26, 250.050 ± 0.63540.052 ± 0.45890.120 ± 0.58000.148 ± 0.4774-0.110 ± 0.6003-0.145 ± 0.4177
Lymphocytes, Week 14, n=29, 30, 33, 34, 27, 230.261 ± 0.90650.021 ± 0.63970.075 ± 0.57120.174 ± 0.7327-0.031 ± 0.67120.109 ± 0.4985
Lymphocytes, EW, n=10, 6, 3, 2, 10, 9-0.164 ± 0.6069-0.078 ± 0.3542-0.113 ± 0.3502-0.185 ± 0.10610.032 ± 0.28620.246 ± 0.4375
Monocytes, Week 2, n=35, 35, 36, 37, 29, 350.029 ± 0.1833-0.061 ± 0.10550.012 ± 0.1314-0.035 ± 0.1117-0.007 ± 0.1583-0.013 ± 0.1083
Monocytes, Week 4, n=31, 34, 35, 37, 29, 31-0.017 ± 0.1241-0.014 ± 0.1706-0.014 ± 0.1226-0.049 ± 0.1119-0.032 ± 0.1972-0.011 ± 0.1464
Monocytes, Week 8, n=30, 30, 32, 37, 27, 260.034 ± 0.1468-0.071 ± 0.1258-0.036 ± 0.1252-0.043 ± 0.1579-0.048 ± 0.1692-0.025 ± 0.1770
Monocytes, Week 12, n=27, 30, 31, 36, 26, 25-0.002 ± 0.1173-0.050 ± 0.1036-0.055 ± 0.1399-0.043 ± 0.1578-0.015 ± 0.1964-0.026 ± 0.1323
Monocytes, Week 14, n=29, 30, 33, 34, 27, 230.031 ± 0.1418-0.009 ± 0.1341-0.057 ± 0.1378-0.054 ± 0.1609-0.025 ± 0.2130-0.017 ± 0.1202
Monocytes, EW, n=10, 6, 3, 2, 10, 90.046 ± 0.1959-0.015 ± 0.1299-0.243 ± 0.2593-0.045 ± 0.10610.006 ± 0.1179-0.084 ± 0.2625
Neutrophils, Week 2, n=35, 35, 36, 37, 29, 350.355 ± 1.72480.310 ± 1.38520.341 ± 1.39140.009 ± 1.3107-0.058 ± 1.80940.107 ± 1.1007
Neutrophils, Week 4, n=31, 34, 35, 37, 29, 310.215 ± 1.58120.139 ± 1.69950.291 ± 1.20830.267 ± 1.33100.049 ± 1.78310.059 ± 1.0011
Neutrophils, Week 8, n=30, 30, 32, 37, 27, 260.402 ± 1.11170.140 ± 1.1014-0.049 ± 1.4021-0.075 ± 1.4243-0.181 ± 1.43590.285 ± 1.3332
Neutrophils, Week 12, n=27, 30, 31, 36, 26, 250.277 ± 1.07850.099 ± 1.3124-0.015 ± 1.4752-0.008 ± 1.43290.043 ± 1.34700.008 ± 1.0432
Neutrophils, Week 14, n=29, 30, 33, 34, 27, 230.158 ± 1.07260.519 ± 1.4793-0.053 ± 1.0828-0.225 ± 1.50590.267 ± 2.2299-0.052 ± 0.8640
Neutrophils, EW, n=10, 6, 3, 2, 10, 90.307 ± 1.1539-0.305 ± 1.35302.727 ± 3.3561-0.735 ± 0.2899-0.285 ± 1.2029-0.019 ± 0.9601
Platelets, Week 2, n=35, 35, 36, 37, 29, 35-0.3 ± 36.305.4 ± 40.502.3 ± 26.06-5.6 ± 47.570.5 ± 29.07-6.1 ± 23.70
Platelets, Week 4, n=32, 34, 35, 37, 29, 31-12.3 ± 39.49-4.1 ± 26.641.9 ± 26.97-1.0 ± 38.162.6 ± 26.00-0.7 ± 28.81
Platelets, Week 8, n=30, 31, 32, 38, 27, 26-6.8 ± 34.57-1.0 ± 23.87-1.8 ± 25.81-11.5 ± 50.010.2 ± 28.94-1.5 ± 23.61
Platelets, Week 12, n=27, 30, 31, 36, 26, 25-10.3 ± 35.25-7.9 ± 24.25-4.9 ± 26.54-15.7 ± 38.39-5.5 ± 38.31-8.9 ± 26.72
Platelets, Week 14, n=29, 30, 33, 34, 27, 23-2.9 ± 18.68-9.6 ± 29.12-2.9 ± 20.21-18.5 ± 41.03-1.7 ± 37.211.2 ± 18.69
Platelets, EW, n=10, 5, 3, 2, 9, 9-2.1 ± 27.63-7.6 ± 13.8937.0 ± 37.80-30.5 ± 48.791.6 ± 22.3623.1 ± 25.21
Leukocytes, Week 2, n=35, 35, 36, 37, 29, 350.50 ± 1.8340.28 ± 1.3810.42 ± 1.6860.12 ± 1.391-0.21 ± 1.8920.08 ± 1.166
Leukocytes, Week 4, n=31, 34, 35, 37, 29, 310.13 ± 1.9720.12 ± 1.7480.31 ± 1.3740.44 ± 1.398-0.14 ± 1.798-0.03 ± 1.059
Leukocytes, Week 8, n=30, 30, 32, 37, 27, 260.49 ± 1.2720.08 ± 1.167-0.14 ± 1.516-0.02 ± 1.604-0.35 ± 1.3920.23 ± 1.527
Leukocytes, Week 12, n=27, 30, 31, 36, 26, 250.36 ± 1.4390.12 ± 1.3590.02 ± 1.4600.10 ± 1.538-0.07 ± 1.301-0.19 ± 1.221
Leukocytes, Week 14, n=29, 30, 33, 34, 27, 230.47 ± 1.4720.54 ± 1.757-0.05 ± 1.256-0.11 ± 1.3800.22 ± 2.172-0.00 ± 1.207
Leukocytes, EW, n=10, 6, 3, 2, 10, 90.21 ± 1.066-0.35 ± 1.3952.13 ± 2.940-0.85 ± 0.354-0.21 ± 1.2600.10 ± 0.505
SecondaryChange From Baseline in Hematocrit Levels

Blood samples were collected for the evaluation of change in hematocrit levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit Levels
Proportion of red blood cells in bloodGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2, n=35, 35, 36, 37, 29, 350.0029 ± 0.0198-0.0036 ± 0.0243-0.0002 ± 0.0251-0.0038 ± 0.0193-0.0063 ± 0.02430.0011 ± 0.0217
Week 4, n=32, 34, 35, 37, 29, 310.0007 ± 0.0227-0.0049 ± 0.02380.0058 ± 0.0283-0.0008 ± 0.02690.0028 ± 0.02910.0054 ± 0.0239
Week 8, n=30, 31, 32, 38, 27, 260.0020 ± 0.02730.0047 ± 0.0274-0.0004 ± 0.0288-0.0036 ± 0.03420.0084 ± 0.02840.0092 ± 0.0319
Week 12, n=27, 30, 31, 36, 26, 250.0045 ± 0.02380.0059 ± 0.02750.0059 ± 0.0235-0.0013 ± 0.02020.0045 ± 0.02250.0084 ± 0.0286
Week 14, n=29, 30, 33, 34, 27, 230.0017 ± 0.0259-0.0010 ± 0.02740.0021 ± 0.0288-0.0120 ± 0.0348-0.0021 ± 0.03360.0035 ± 0.0186
EW, n=10, 6, 3, 2, 10, 90.0014 ± 0.0185-0.0273 ± 0.0221-0.0093 ± 0.0134-0.0050 ± 0.0014-0.0017 ± 0.01610.0014 ± 0.0268
SecondaryChange From Baseline in Hemoglobin (Hgb) Level and Erythrocyte Mean Corpuscular Hgb Concentration (MCHC)

Blood samples were collected for the evaluation of change in Hgb levels and MCHC from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · G/L
Change From Baseline in Hemoglobin (Hgb) Level and Erythrocyte Mean Corpuscular Hgb Concentration (MCHC)
G/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Hgb, Week 2, n=35, 35, 36, 37, 29, 350.3 ± 5.84-1.6 ± 6.98-1.4 ± 7.51-0.6 ± 6.29-1.3 ± 7.790.1 ± 6.18
Hgb, Week 4, n=32, 34, 35, 37, 29, 31-1.0 ± 6.02-2.5 ± 5.860.3 ± 8.74-0.1 ± 8.82-0.7 ± 8.771.0 ± 5.68
Hgb, Week 8, n=30, 31, 32, 38, 27, 26-1.8 ± 6.180.1 ± 6.78-2.8 ± 9.06-2.1 ± 9.171.0 ± 8.821.2 ± 7.73
Hgb, Week 12, n=27, 30, 31, 36, 26, 25-1.3 ± 5.74-0.8 ± 6.86-1.9 ± 8.76-2.4 ± 5.94-1.0 ± 7.650.2 ± 6.27
Hgb, Week 14, n=29, 30, 33, 34, 27, 23-1.9 ± 7.85-2.7 ± 7.54-2.6 ± 8.64-5.0 ± 10.24-2.8 ± 8.82-1.6 ± 5.94
Hgb, EW, n=10, 6, 3, 2, 10, 90.0 ± 7.26-7.8 ± 8.73-5.7 ± 3.79-1.5 ± 0.71-2.3 ± 4.99-0.1 ± 6.13
MCHC, Week 2, n=35, 35, 36, 37, 29, 35-1.5 ± 8.77-1.3 ± 9.44-3.0 ± 10.321.0 ± 7.150.9 ± 7.99-0.5 ± 7.10
MCHC, Week 4, n=32, 34, 35, 37, 29, 31-3.1 ± 11.45-2.1 ± 9.88-3.6 ± 10.600.4 ± 8.36-3.8 ± 9.19-1.6 ± 10.02
MCHC, Week 8, n=30, 31, 32, 38, 27, 26-5.4 ± 11.25-3.2 ± 12.76-5.9 ± 13.41-2.3 ± 11.29-4.4 ± 10.65-3.8 ± 11.40
MCHC, Week 12, n=27, 30, 31, 36, 26, 25-6.1 ± 12.65-6.1 ± 11.25-8.6 ± 11.49-4.8 ± 10.39-5.9 ± 10.14-5.0 ± 10.74
MCHC, Week 14, n=29, 30, 33, 34, 27, 23-5.4 ± 8.55-5.5 ± 9.15-7.4 ± 10.74-2.7 ± 9.40-5.3 ± 9.27-5.9 ± 9.79
MCHC, EW, n=10, 6, 3, 2, 10, 9-1.1 ± 11.571.5 ± 8.50-6.3 ± 9.070.0 ± 0.00-4.1 ± 4.12-1.3 ± 9.10
SecondaryChange From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Level

Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular hemoglobin level from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · Picogram (pg)
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Level
Picogram (pg)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2, n=35, 35, 36, 37, 29, 350.10 ± 0.4930.05 ± 0.408-0.08 ± 0.5900.11 ± 0.733-0.10 ± 1.519-0.01 ± 0.605
Week 4, n=32, 34, 35, 37, 29, 310.01 ± 0.562-0.06 ± 0.517-0.19 ± 0.7500.08 ± 0.774-0.15 ± 1.257-0.15 ± 0.863
Week 8, n=30, 31, 32, 38, 27, 260.13 ± 0.6080.31 ± 2.220-0.20 ± 0.805-0.04 ± 0.803-0.13 ± 1.286-0.09 ± 0.753
Week 12, n=27, 30, 31, 36, 26, 250.20 ± 0.804-0.07 ± 0.672-0.15 ± 0.532-0.00 ± 0.837-0.30 ± 1.265-0.21 ± 0.764
Week 14, n=29, 30, 33, 34, 27, 230.39 ± 0.6710.02 ± 0.406-0.19 ± 0.6850.07 ± 0.785-0.23 ± 1.3960.01 ± 0.557
EW, n=10, 6, 3, 2, 10, 90.10 ± 0.3710.15 ± 0.734-0.50 ± 0.5200.05 ± 0.071-0.02 ± 0.181-0.12 ± 0.533
SecondaryChange From Baseline in Erythrocyte Mean Corpuscular Volume

Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular volume from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · Femtoliter (fL)
Change From Baseline in Erythrocyte Mean Corpuscular Volume
Femtoliter (fL)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2, n=35, 35, 36, 37, 29, 350.7 ± 2.380.6 ± 2.070.6 ± 2.390.1 ± 2.11-0.5 ± 4.050.2 ± 1.96
Week 4, n=32, 34, 35, 37, 29, 310.8 ± 2.210.4 ± 1.940.4 ± 2.650.2 ± 2.390.7 ± 3.730.0 ± 3.10
Week 8, n=30, 31, 32, 38, 27, 262.0 ± 2.392.0 ± 5.051.1 ± 3.570.6 ± 3.410.9 ± 3.800.9 ± 3.10
Week 12, n=27, 30, 31, 36, 26, 252.4 ± 2.271.6 ± 1.941.9 ± 3.411.4 ± 3.720.8 ± 3.980.9 ± 2.93
Week 14, n=29, 30, 33, 34, 27, 232.7 ± 2.871.6 ± 2.081.5 ± 3.040.9 ± 3.270.9 ± 3.951.9 ± 2.36
EW, n=10, 6, 3, 2, 10, 90.6 ± 3.410.0 ± 2.19-0.3 ± 0.58-0.5 ± 0.711.1 ± 1.600.1 ± 2.42
SecondaryChange From Baseline in Erythrocyte Count

Blood samples were collected for the evaluation of change in erythrocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · Tetra unit/L (TI/L)
Change From Baseline in Erythrocyte Count
Tetra unit/L (TI/L)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 2, n=35, 35, 36, 37, 29, 35-0.01 ± 0.180-0.06 ± 0.243-0.04 ± 0.315-0.05 ± 0.210-0.03 ± 0.3630.01 ± 0.269
Week 4, n=32, 34, 35, 37, 29, 31-0.03 ± 0.213-0.06 ± 0.2200.02 ± 0.358-0.01 ± 0.2690.01 ± 0.4210.05 ± 0.294
Week 8, n=30, 31, 32, 38, 27, 26-0.09 ± 0.273-0.05 ± 0.468-0.07 ± 0.306-0.07 ± 0.2570.06 ± 0.3560.03 ± 0.317
Week 12, n=27, 30, 31, 36, 26, 25-0.07 ± 0.2370.00 ± 0.257-0.05 ± 0.356-0.08 ± 0.2280.00 ± 0.3280.04 ± 0.229
Week 14, n=29, 30, 33, 34, 27, 23-0.13 ± 0.334-0.09 ± 0.252-0.07 ± 0.374-0.18 ± 0.343-0.06 ± 0.370-0.07 ± 0.194
EW, n=10, 6, 3, 2, 10, 9-0.03 ± 0.250-0.30 ± 0.268-0.13 ± 0.153-0.10 ± 0.000-0.07 ± 0.2000.00 ± 0.212
SecondaryNumber of Participants With Chemistry Data of Potential Clinical Importance

Blood samples were collected for the evaluation of clinical chemistry parameters including alk phos, ALT, AST, bil, calcium, CO2, creatinine, glucose and potassium. The number of participants with chemistry data of potential clinical importance for the mentioned parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 14
Reported as:
Number · Participants
Number of Participants With Chemistry Data of Potential Clinical Importance
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Alk. Phos, Baseline, n=38, 38, 38, 38, 37, 38000000
Alk. Phos, Week 2, n=35, 36, 35, 37, 29, 34000000
Alk. Phos, Week 4, n=32, 34, 33, 37, 29, 30001000
Alk. Phos, Week 8, n=30, 31, 32, 37, 27, 26000000
Alk. Phos, Week 12, n=27, 30, 32, 36, 26, 24000000
Alk. Phos, Week 14, n=29, 31, 33, 34, 27, 24000000
Alk. Phos, EW, n=10, 6, 3, 2, 10, 9000000
Alk. Phos,post-screen(PS),n=38, 37, 37, 38, 36, 36001000
ALT, Baseline, n=38, 38, 38, 38, 37, 38000000
ALT, Week 2, n=35, 36, 35, 37, 29, 34000001
ALT, Week 4, n=32, 34, 33, 37, 29, 30100001
ALT, Week 8, n=30, 31, 32, 37, 27, 26000000
ALT, Week 12, n=27, 30, 32, 36, 26, 24000001
ALT, Week 14, n=29, 31, 33, 34, 27, 24000000
ALT, EW, n=10, 6, 3, 2, 10, 9000000
ALT, PS, n=38, 37, 37, 38, 36, 36100002
AST, Baseline, n=38, 38, 38, 38, 37, 38010000
AST, Week 2, n=35, 36, 35, 37, 29, 34010000
AST, Week 4, n=32, 34, 33, 37, 29, 30000000
AST, Week 8, n=30, 31, 32, 37, 27, 26010000
AST, Week 12, n=27, 30, 32, 36, 26, 24000000
AST, Week 14, n=29, 31, 33, 34, 27, 24000000
AST, EW, n=10, 6, 3, 2, 10, 9000000
AST, PS, n=38, 37, 37, 38, 36, 36020000
Bil, Baseline, n=38, 38, 38, 38, 37, 38000001
Bil, Week 2, n=35, 36, 35, 37, 29, 34000011
Bil, Week 4, n=32, 34, 33, 37, 29, 30000001
Bil, Week 8, n=30, 31, 32, 37, 27, 26000001
Bil, Week 12, n=27, 30, 32, 36, 26, 24000001
Bil, Week 14, n=29, 31, 33, 34, 27, 24000001
Bil, EW, n=10, 6, 3, 2, 10, 9000000
Bil, PS, n=38, 37, 37, 38, 36, 36000011
Calcium, Baseline, n=38, 38, 38, 38, 37, 38000000
Calcium, Week 2, n=35, 36, 35, 37, 29, 34001000
Calcium, Week 4, n=32, 34, 33, 37, 29, 30000000
Calcium, Week 8, n=30, 31, 32, 37, 27, 26001000
Calcium, Week 12, n=27, 30, 32, 36, 26, 24000100
Calcium, Week 14, n=29, 31, 33, 34, 27, 24000000
Calcium, EW, n=10, 6, 3, 2, 10, 9000000
Calcium, PS, n=38, 37, 37, 38, 36, 36002100
CO2, Baseline, n=38, 38, 38, 38, 37, 38001000
CO2, Week 2, n=35, 36, 35, 37, 29, 34104100
CO2, Week 4, n=32, 34, 33, 37, 29, 30013000
CO2, Week 8, n=30, 31, 32, 37, 27, 26111000
CO2, Week 12, n=27, 30, 32, 36, 26, 24003100
CO2, Week 14, n=29, 31, 33, 34, 27, 24001100
CO2, EW, n=10, 6, 3, 2, 10, 9000000
CO2, PS, n=38, 37, 37, 38, 36, 36118200
Creatinine, Baseline, n=38, 38, 38, 38, 37, 38000000
Creatinine, Week 2, n=35, 36, 35, 37, 29, 34000000
Creatinine, Week 4, n=32, 34, 33, 37, 29, 30000000
Creatinine, Week 8, n=30, 31, 32, 37, 27, 26000100
Creatinine, Week 12, n=27, 30, 32, 36, 26, 24000000
Creatinine, Week 14, n=29, 31, 33, 34, 27, 24000000
Creatinine, EW, n=10, 6, 3, 2, 10, 9001000
Creatinine, PS, n=38, 37, 37, 38, 36, 36001100
Glucose, Baseline, n=38, 38, 38, 38, 37, 38045251
Glucose, Week 2, n=35, 36, 35, 37, 29, 34255222
Glucose, Week 4, n=32, 34, 33, 37, 29, 30444353
Glucose, Week 8, n=30, 31, 32, 37, 27, 26136243
Glucose, Week 12, n=27, 30, 32, 36, 26, 24337422
Glucose, Week 14, n=29, 31, 33, 34, 27, 24127453
Glucose, EW, n=10, 6, 3, 2, 10, 9100000
Glucose, PS, n=38, 37, 37, 38, 36, 36777869
Potassium, Baseline, n=38, 38, 38, 38, 37, 38000000
Potassium, Week 2, n=35, 36, 35, 37, 29, 34001010
Potassium, Week 4, n=32, 34, 33, 37, 29, 30100021
Potassium, Week 8, n=30, 31, 32, 37, 27, 26010002
Potassium, Week 12, n=27, 30, 32, 36, 26, 24001000
Potassium, Week 14, n=29, 31, 33, 34, 27, 24000000
Potassium, EW, n=10, 6, 3, 2, 10, 9000000
Potassium, PS, n=38, 37, 37, 38, 36, 36111022
SecondaryNumber of Participants With Hematology Data of Clinical Importance

Blood samples were collected for the evaluation of hematology parameters including hematocrit, Hgb, lymphocytes, neutrophils and platelets. The number of participants with clinically significant abnormal values of the mentioned hematology parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 14
Reported as:
Number · Participants
Number of Participants With Hematology Data of Clinical Importance
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Hematocrit,Baseline, n=38, 38, 38, 38, 37, 38000200
Hematocrit, Week 2, n=35, 35, 36, 37, 29, 35100200
Hematocrit, Week 4, n=32, 34, 35, 37, 29, 31001200
Hematocrit, Week 8, n=30, 31, 32, 38, 27, 26000201
Hematocrit, Week 12, n=27, 30, 31, 36, 26, 25000200
Hematocrit, Week 14, n=29, 30, 33, 34, 27, 23100110
Hematocrit, EW, n=10, 6, 3, 2, 10, 9000000
Hematocrit, PS, n=38, 37, 37, 38, 36, 36201311
Hgb,Baseline, n=38, 38, 38, 38, 37, 38000000
Hgb, Week 2, n=35, 35, 36, 37, 29, 35000100
Hgb, Week 4, n=32, 34, 35, 37, 29, 31000100
Hgb, Week 8, n=30, 31, 32, 38, 27, 26000200
Hgb, Week 12, n=27, 30, 31, 36, 26, 25000000
Hgb, Week 14, n=29, 30, 33, 34, 27, 23100100
Hgb, EW, n=10, 6, 3, 2, 10, 9000000
Hgb, PS, n=38, 37, 37, 38, 36, 36100200
Lymphocytes, Baseline, n=38, 38, 38, 38, 37, 38000000
Lymphocytes, Week 2, n=35, 35, 36, 37, 29, 35000001
Lymphocytes, Week 4, n=31, 34, 35, 37, 29, 31010001
Lymphocytes, Week 8, n=30, 30, 32, 37, 27, 26000001
Lymphocytes, Week 12, n=27, 30, 31, 36, 26, 25000010
Lymphocytes, Week 14, n=29, 30, 33, 34, 27, 23010000
Lymphocytes, EW, n=10, 6, 3, 2, 10, 9000000
Lymphocytes, PS, n=38, 37, 37, 38, 36, 36010011
Neutrophils,Baseline, n=38, 38, 38, 38, 37, 38001000
Neutrophils, Week 2, n=35, 35, 36, 37, 29, 35000000
Neutrophils, Week 4, n=31, 34, 35, 37, 29, 31000000
Neutrophils, Week 8, n=30, 30, 32, 37, 27, 26000000
Neutrophils, Week 12, n=27, 30, 31, 36, 26, 25000000
Neutrophils, Week 14, n=29, 30, 33, 34, 27, 23000000
Neutrophils, EW, n=10, 6, 3, 2, 10, 9000000
Neutrophils, PS, n=38, 37, 37, 38, 36, 36000000
Platelets,Baseline, n=38, 38, 38, 38, 37, 38010000
Platelets, Week 2, n=35, 35, 36, 37, 29, 35010000
Platelets, Week 4, n=32, 34, 35, 37, 29, 31000010
Platelets, Week 8, n=30, 31, 32, 38, 27, 26000010
Platelets, Week 12, n=27, 30, 31, 36, 26, 25000010
Platelets, Week 14, n=29, 30, 33, 34, 27, 23000000
Platelets, EW, n=10, 5, 3, 2, 9, 9010000
Platelets, PS, n=38, 37, 37, 38, 35, 36010010
SecondaryChange From Baseline in Immunoglobulin (Ig) A, IgG and IgM Levels

Blood samples were collected for the evaluation of change in IgA, IgG and IgM levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 12
Reported as:
Mean · g/L
Change From Baseline in Immunoglobulin (Ig) A, IgG and IgM Levels
g/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
IgA, Week 4, n=32, 34, 35, 38, 29, 31-0.035 ± 0.2151-0.138 ± 0.3147-0.153 ± 0.5744-0.024 ± 0.61500.125 ± 0.54620.006 ± 0.2350
IgA, Week 8, n=30, 31, 33, 38, 27, 260.021 ± 0.3615-0.151 ± 0.3497-0.239 ± 0.6447-0.064 ± 0.63530.086 ± 0.6911-0.050 ± 0.4347
IgA, Week 12, n=27, 30, 32, 36, 26, 24-0.028 ± 0.2806-0.138 ± 0.2461-0.271 ± 0.6764-0.037 ± 1.0705-0.023 ± 0.8912-0.018 ± 0.2355
IgG, Week 4, n=32, 34, 35, 38, 29, 310.130 ± 0.8150-0.223 ± 1.04220.117 ± 1.40030.028 ± 1.71570.441 ± 1.66550.218 ± 1.1025
IgG, Week 8, n=30, 31, 33, 38, 27, 26-0.098 ± 1.1559-0.055 ± 1.1243-0.016 ± 1.40660.195 ± 1.43300.634 ± 1.49130.299 ± 1.3855
IgG, Week 12, n=27, 30, 32, 36, 26, 240.248 ± 0.89370.029 ± 1.1145-0.360 ± 1.36830.251 ± 1.41150.377 ± 2.05390.283 ± 1.0979
IgM, Week 4, n=32, 34, 35, 38, 29, 31-0.077 ± 0.1215-0.050 ± 0.0797-0.023 ± 0.3524-0.017 ± 0.1434-0.004 ± 0.1951-0.016 ± 0.1371
IgM, Week 8, n=30, 31, 33, 38, 27, 26-0.103 ± 0.1649-0.030 ± 0.1737-0.005 ± 0.4892-0.012 ± 0.1213-0.011 ± 0.1951-0.006 ± 0.1802
IgM, Week 12, n=27, 30, 32, 36, 26, 24-0.072 ± 0.0992-0.082 ± 0.1264-0.047 ± 0.5307-0.017 ± 0.1495-0.023 ± 0.2431-0.033 ± 0.1900
SecondaryNumber of Participants With Ig Data Outside the Reference Range

Blood samples were collected for the evaluation of change in Ig levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 12
Reported as:
Number · Participants
Number of Participants With Ig Data Outside the Reference Range
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
IgA, Baseline, n=38, 38, 38, 38, 37, 38213422
IgA, Week 4, n=32, 34, 35, 38, 29, 31111221
IgA, Week 8, n=30, 31, 33, 38, 27, 26111211
IgA, Week 12, n=27, 30, 32, 36, 26, 24012301
IgA, PS, n=33, 34, 36, 38, 29, 31212321
IgG, Baseline, n=38, 38, 38, 38, 37, 38423214
IgG, Week 4, n=32, 34, 35, 38, 29, 31323304
IgG, Week 8, n=30, 31, 33, 38, 27, 26324214
IgG, Week 12, n=27, 30, 32, 36, 26, 24214412
IgG, PS, n=33, 34, 36, 38, 29, 31325414
IgM, Baseline, n=38, 38, 38, 38, 37, 381159325
IgM, Week 4, n=32, 34, 35, 38, 29, 31959423
IgM, Week 8, n=30, 31, 33, 38, 27, 26968424
IgM, Week 12, n=27, 30, 32, 36, 26, 24858322
IgM, PS, n=33, 34, 36, 38, 29, 3111610534
SecondaryNumber of Participants With Immunophenotyping Data Outside the Reference Range

Blood samples were collected for the evaluation of change in levels of cluster of differentiation (CD)19, CD3, CD3 Treg flow cytometry (CD3TFLC), CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T Cell B Cell Natural Killer Lymphocytes flow cytometry (T-B cell NKL). Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 12
Reported as:
Number · Participants
Number of Participants With Immunophenotyping Data Outside the Reference Range
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
CD19, Baseline, n=38, 38, 38, 38, 37, 385557111
CD19, Week 4, n=30, 32, 35, 38, 29, 30264663
CD19, Week 8, n=30, 31, 33, 38, 27, 26456652
CD19, Week 12, n=27, 29, 32, 36, 26, 24244461
CD19, PS, n=33, 34, 36, 38, 29, 31578794
CD3, Baseline, n=38, 38, 38, 38, 37, 38435312
CD3, Week 4, n=30, 32, 35, 38, 29, 30114002
CD3, Week 8, n=30, 31, 33, 38, 27, 26214212
CD3, Week 12, n=27, 29, 32, 36, 26, 24123220
CD3, PS, n=33, 34, 36, 38, 29, 31348323
CD3 TFLC, Baseline, n=37,36,38, 38, 36, 38000000
CD3 TFLC, Week 4, n=28, 30, 32, 36, 28, 26010000
CD3 TFLC, Week 8, n=30, 29, 31, 34, 25, 22010000
CD3 TFLC, Week 12, n=26,26,30, 34, 24, 24010000
CD3 TFLC, PS, n=33, 33, 36, 38, 29, 31010000
CD3+CD8+, Baseline, n=38, 38, 38, 38, 37, 38042335
CD3+CD8+, Week 4, n=30, 32, 35, 38, 29, 30033203
CD3+CD8+, Week 8, n=30, 31, 33, 38, 27, 26030133
CD3+CD8+, Week 12, n=27, 29, 32, 36, 26, 24020122
CD3+CD8+, PS, n=33, 34, 36, 38, 29, 31043335
CD3+CD8+ TFLC, Baseline, n=37, 36, 38, 38, 36, 38000000
CD3+CD8+ TFLC, Week 4, n=28, 30, 32, 36, 28, 36010010
CD3+CD8+ TFLC, Week 8, n=30, 29, 31, 34, 25, 22010110
CD3+CD8+ TFLC, Week 12, n=26, 26, 30, 34, 24, 24010000
CD3+CD8+TFLC, PS, n=33, 33,36, 38, 29, 31011220
CD3+CD4+, Baseline, n=38, 38, 38, 38, 37, 38654221
CD3+CD4+, Week 4, n=30, 32, 35, 38, 29, 30315313
CD3+CD4+, Week 8, n=30, 31, 33, 38, 27, 26333221
CD3+CD4+, Week 12, n=27, 29, 32, 36, 26, 24124210
CD3+CD4+, PS, n=33, 34, 36, 38, 29, 31568553
CD3+CD4+ TFLC, Baseline, n=37, 36, 38, 38, 36, 38000000
CD3+CD4+ TFLC, Week 4, n=28, 30, 32, 36, 28, 36010000
CD3+CD4+ TFLC, Week 8, n=30, 29, 31, 34, 25, 22010000
CD3+CD4+ TFLC, Week 12, n=26, 26, 30, 34, 24, 24010000
CD3+CD4+ TF, PS, n=33, 33, 36, 38, 29, 31010000
CD16+CD56+, Baseline, n=38, 38, 38, 38, 37, 38000101
CD16+CD56+, Week 4, n=30, 32, 35, 38, 29, 30100001
CD16+CD56+, Week 8, n=30, 31, 33, 38, 27, 26000011
CD16+CD56+, Week 12, n=27, 29, 32, 36, 26, 24100001
CD16+CD56+, PS, n=33, 34, 36, 38, 29, 31101211
CD3+CD4+CD25+CD127, Baseline, n=37,36,38,38,36,38000000
CD3+CD4+CD25+CD127, Week 4, n=28,30,32,36,28,36131350
CD3+CD4+CD25+CD127, Week 8, n=30,29,31,34,25,22041250
CD3+CD4+CD25+CD127, Week 12, n=26,26,30,34,24,24061750
CD3+CD4+CD25+CD127, PS, n=33,33,36,38,29,31171972
CD3+CD4+fP3+CD25+CD127Baseline,n=37,36,38,38,36,38000000
CD3+CD4+fP3+CD25+CD127, Week 4,n=28,30,32,36,28,36584573
CD3+CD4+fP3+CD25+CD127, Week 8,n=30,29,31,34,25,22676654
CD3+CD4+fP3+CD25+CD127 Week 12,n=26,26,30,34,24,24463822
CD3+CD4+fP3+CD25+CD127, PS,n=33,33,36,38,29,3111141215117
T-B cell NKL, Baseline, n=38,38,38,38,37,38110110
T-B cell NKL, Week 4, n=30,32,35,38,29,30011001
T-B cell NKL, Week 8, n=30,31,33,38,27,26001001
T-B cell NKL, Week 12, n=27,29,32,36,26,24000010
T-B cell NKL, PS, n=33,34,36,38,29,31012011
SecondaryChange From Baseline in Immunophenotype Data

Blood samples were collected for the evaluation of change from Baseline in immunophenotype levels including CD19, CD3, CD3TFLC, CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T-B cell NKL. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 12
Reported as:
Mean · GI/L
Change From Baseline in Immunophenotype Data
GI/LGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
CD19, Week 4, n=30, 32, 35, 38, 29, 30-0.0182 ± 0.10600.0318 ± 0.1046-0.0261 ± 0.1177-0.0184 ± 0.2460-0.0241 ± 0.3210-0.0109 ± 0.0659
CD19, Week 8, n=30, 31, 33, 38, 27, 260.0367 ± 0.12840.0491 ± 0.0984-0.0288 ± 0.0953-0.0464 ± 0.2220-0.0533 ± 0.28780.0150 ± 0.1099
CD19, Week 12, n=27, 29, 32, 36, 26, 240.0059 ± 0.11780.0362 ± 0.0968-0.0334 ± 0.0968-0.0305 ± 0.2591-0.0443 ± 0.2863-0.0097 ± 0.0774
CD3, Week 4, n=30, 32, 35, 38, 29, 30-0.1067 ± 0.39640.1044 ± 0.3945-0.0360 ± 0.34190.0186 ± 0.3417-0.0842 ± 0.2888-0.0584 ± 0.3175
CD3, Week 8, n=30, 31, 33, 38, 27, 260.0227 ± 0.43180.1426 ± 0.3650-0.0101 ± 0.3231-0.0053 ± 0.3463-0.1063 ± 0.4996-0.0213 ± 0.2936
CD3, Week 12, n=27, 29, 32, 36, 26, 24-0.0511 ± 0.42250.1327 ± 0.4230-0.0248 ± 0.3140-0.0315 ± 0.3259-0.0822 ± 0.3222-0.0142 ± 0.3345
CD3 TFLC, Week 4, n=27, 29, 32, 36, 28, 26-0.0829 ± 0.40020.1270 ± 0.42330.0196 ± 0.31040.0320 ± 0.3412-0.0937 ± 0.3115-0.1031 ± 0.3504
CD3 TFLC, Week 8, n=29, 27, 31, 34, 25, 220.0187 ± 0.47490.1296 ± 0.3352-0.0158 ± 0.35030.0053 ± 0.2782-0.1393 ± 0.5368-0.0383 ± 0.3471
CD3 TFLC, Week 12, n=25,24,30, 34, 24, 24-0.0916 ± 0.44660.1494 ± 0.4745-0.0266 ± 0.3227-0.0342 ± 0.3157-0.1220 ± 0.3010-0.0280 ± 0.3630
CD3+CD8+, Week 4, n=30, 32, 35, 38, 29, 30-0.0297 ± 0.13940.0524 ± 0.15160.0094 ± 0.12790.0095 ± 0.1217-0.0009 ± 0.18710.0179 ± 0.1504
CD3+CD8+, Week 8, n=30, 31, 33, 38, 27, 260.0001 ± 0.15820.0683 ± 0.16970.0100 ± 0.10060.0219 ± 0.1550-0.0189 ± 0.20730.0566 ± 0.1508
CD3+CD8+, Week 12, n=27, 29, 32, 36, 26, 24-0.0174 ± 0.14170.0477 ± 0.16420.0106 ± 0.12530.0151 ± 0.15940.0081 ± 0.19200.0326 ± 0.1690
CD3+CD8+ TFLC, Week 4, n=27, 29, 32, 36, 28, 26-0.0203 ± 0.12640.0359 ± 0.17190.0083 ± 0.0980-0.0069 ± 0.1480-0.0107 ± 0.1759-0.0180 ± 0.1055
CD3+CD8+ TFLC, Week 8, n=29, 27, 31, 34, 25, 22-0.0066 ± 0.14200.0375 ± 0.16280.0091 ± 0.09200.0035 ± 0.1194-0.0254 ± 0.20650.0139 ± 0.1195
CD3+CD8+ TFLC, Week 12, n=25, 24, 30, 34, 24, 24-0.0306 ± 0.12840.0260 ± 0.1760-0.0042 ± 0.11130.0010 ± 0.1518-0.0112 ± 0.14930.0193 ± 0.1535
CD3+CD4+, Week 4, n=30, 32, 35, 38, 29, 30-0.0750 ± 0.27560.0525 ± 0.2577-0.0374 ± 0.24290.0210 ± 0.2475-0.0857 ± 0.1802-0.0775 ± 0.2286
CD3+CD4+, Week 8, n=30, 31, 33, 38, 27, 260.0296 ± 0.30060.0758 ± 0.2036-0.0042 ± 0.2396-0.0164 ± 0.2338-0.0821 ± 0.3158-0.0715 ± 0.2205
CD3+CD4+, Week 12, n=27, 29, 32, 36, 26, 24-0.0228 ± 0.29280.0936 ± 0.2664-0.0225 ± 0.2149-0.0249 ± 0.2005-0.0798 ± 0.1817-0.0458 ± 0.1960
CD3+CD4+ TFLC, Week 4, n=27, 29, 32, 36, 28, 26-0.0512 ± 0.24930.0764 ± 0.26130.0009 ± 0.21210.0280 ± 0.2521-0.0729 ± 0.1786-0.0621 ± 0.2216
CD3+CD4+ TFLC, Week 8, n=29, 27, 31, 34, 25, 220.0268 ± 0.31340.0857 ± 0.1814-0.0075 ± 0.25250.0138 ± 0.2066-0.0784 ± 0.3136-0.0298 ± 0.2089
CD3+CD4+ TFLC, Week 12, n=25, 24, 30, 34, 24, 24-0.0511 ± 0.28350.1196 ± 0.2891-0.0159 ± 0.22440.0044 ± 0.1730-0.0679 ± 0.1740-0.0386 ± 0.1832
CD16+CD56+, Week 4, n=30, 32, 35, 38, 29, 30-0.023 ± 0.09100.014 ± 0.10310.011 ± 0.0897-0.009 ± 0.0821-0.013 ± 0.11340.001 ± 0.0876
CD16+CD56+, Week 8, n=30, 31, 33, 38, 27, 260.002 ± 0.06990.011 ± 0.13120.009 ± 0.0867-0.002 ± 0.0713-0.000 ± 0.18000.013 ± 0.1339
CD16+CD56+, Week 12, n=27, 29, 32, 36, 26, 24-0.010 ± 0.0861-0.001 ± 0.1283-0.015 ± 0.0861-0.022 ± 0.1082-0.035 ± 0.11680.024 ± 0.0792
CD3+CD4+CD25+CD127, Week 4, n=27,29,32,36,28,260.0016 ± 0.01090.0021 ± 0.01950.0019 ± 0.0147-0.0036 ± 0.0218-0.0016 ± 0.0172-0.0008 ± 0.0097
CD3+CD4+CD25+CD127, Week 8, n=29,27,31,34,25,220.0002 ± 0.01410.0040 ± 0.02280.0027 ± 0.0133-0.0019 ± 0.0200-0.0034 ± 0.02050.0020 ± 0.0122
CD3+CD4+CD25+CD127, Week 12, n=25,24,30,34,24,240.0060 ± 0.01210.0035 ± 0.02790.0029 ± 0.0164-0.0035 ± 0.0229-0.0037 ± 0.0141-0.0010 ± 0.0106
CD3+CD4+fP3+CD25+CD127, Week4,n=27,29,32,36,28,26-0.0019 ± 0.01180.0057 ± 0.01100.0018 ± 0.0107-0.0024 ± 0.0130-0.0005 ± 0.0115-0.0003 ± 0.0104
CD3+CD4+fP3+CD25+CD127, Week 8,n=29,27,31,34,25,22-0.0006 ± 0.01700.0055 ± 0.01210.0004 ± 0.01180.0055 ± 0.01340.0003 ± 0.0107-0.0000 ± 0.0100
CD3+CD4+fP3+CD25+CD127 Week12,n=25,24,30,34,24,240.0063 ± 0.01150.0041 ± 0.01470.0005 ± 0.0127-0.0001 ± 0.01250.0001 ± 0.00990.0001 ± 0.0124
T-B cell NKL, Week 4, n=30,32,35,38,29,30-0.157 ± 0.55370.152 ± 0.5655-0.051 ± 0.4505-0.009 ± 0.4837-0.137 ± 0.4446-0.083 ± 0.4134
T-B cell NKL, Week 8, n=30,31,33,38,27,260.057 ± 0.56990.195 ± 0.5345-0.028 ± 0.4384-0.064 ± 0.4563-0.186 ± 0.49990.006 ± 0.4809
T-B cell NKL, Week 12, n=27,29,32,36,26,24-0.063 ± 0.57930.163 ± 0.6093-0.081 ± 0.4282-0.094 ± 0.5229-0.193 ± 0.40380.008 ± 0.4342
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · Millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeter of mercury (mmHg)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
SBP, Week 1, n=36, 38, 37, 38, 35, 37-1.4 ± 10.54-0.8 ± 10.541.6 ± 10.082.1 ± 6.971.4 ± 11.181.1 ± 11.16
SBP, Week 2, n=36, 36, 36, 38, 31, 35-2.0 ± 11.61-1.0 ± 11.453.0 ± 10.73-0.1 ± 9.790.6 ± 13.73-1.1 ± 13.15
SBP, Week 4, n=32, 34, 35, 38, 29, 310.4 ± 12.40-2.0 ± 12.682.6 ± 11.54-1.4 ± 8.35-0.3 ± 13.35-0.3 ± 13.22
SBP, Week 8, n=30, 31, 33, 38, 27, 264.0 ± 12.11-1.6 ± 14.254.0 ± 14.690.3 ± 13.420.4 ± 13.342.4 ± 13.81
SBP, Week 12, n=26, 30, 32, 36, 26, 253.4 ± 14.09-1.5 ± 14.881.1 ± 12.97-0.6 ± 9.512.0 ± 11.161.2 ± 12.02
SBP, Week 14, n=29, 31, 33, 34, 27, 26-0.3 ± 13.10-0.9 ± 14.442.6 ± 11.66-1.1 ± 9.70-2.4 ± 15.052.2 ± 10.97
SBP, EW, n=10, 7, 4, 2, 10, 95.3 ± 14.730.4 ± 17.221.3 ± 8.73-10.5 ± 2.12-1.3 ± 16.15-4.0 ± 13.19
DBP, Week 1, n=36, 38, 37, 38, 35, 370.9 ± 7.70-0.2 ± 7.640.4 ± 6.611.5 ± 7.481.5 ± 10.14-0.8 ± 8.27
DBP, Week 2, n=36, 36, 36, 38, 31, 350.5 ± 8.130.3 ± 7.552.3 ± 6.520.3 ± 7.111.2 ± 9.510.0 ± 7.94
DBP, Week 4, n=32, 34, 35, 38, 29, 311.0 ± 8.040.7 ± 7.531.2 ± 6.79-0.2 ± 5.77-1.8 ± 9.32-0.2 ± 7.54
DBP, Week 8, n=30, 31, 33, 38, 27, 260.1 ± 6.441.4 ± 9.172.1 ± 7.260.9 ± 9.660.6 ± 8.420.6 ± 8.18
DBP, Week 12, n=26, 30, 32, 36, 26, 252.4 ± 9.981.3 ± 9.001.0 ± 8.280.3 ± 8.020.1 ± 8.60-0.1 ± 7.98
DBP, Week 14, n=29, 31, 33, 34, 27, 260.3 ± 8.802.5 ± 8.272.2 ± 5.56-0.1 ± 7.64-1.1 ± 9.450.2 ± 9.85
DBP, EW, n=10, 7, 4, 2, 10, 93.4 ± 6.221.4 ± 7.323.5 ± 5.973.5 ± 16.261.2 ± 11.49-1.1 ± 6.13
SecondaryChange From Baseline in Pulse Rate

Pulse rate was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate
beats per minuteGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=36, 38, 37, 38, 35, 370.5 ± 8.82-0.4 ± 9.401.7 ± 7.07-0.1 ± 9.18-0.0 ± 7.65-0.6 ± 9.96
Week 2, n=36, 36, 36, 38, 31, 350.9 ± 10.33-3.2 ± 9.771.4 ± 7.731.7 ± 9.76-1.5 ± 11.511.6 ± 10.40
Week 4, n=32, 34, 35, 38, 29, 311.2 ± 8.08-0.9 ± 8.080.8 ± 7.131.5 ± 9.782.4 ± 11.14-1.7 ± 7.59
Week 8, n=30, 31, 33, 38, 27, 26-0.4 ± 8.06-0.9 ± 7.590.2 ± 8.021.3 ± 9.382.8 ± 10.540.2 ± 10.28
Week 12, n=26, 30, 32, 36, 26, 250.1 ± 9.16-2.2 ± 10.181.4 ± 8.180.6 ± 9.801.2 ± 11.752.6 ± 8.04
Week 14, n=29, 31, 33, 34, 27, 26-0.6 ± 8.52-0.8 ± 8.270.2 ± 9.20-0.1 ± 8.48-0.1 ± 11.141.3 ± 6.24
EW, n=10, 7, 4, 2, 10, 9-2.2 ± 4.54-2.7 ± 9.25-2.5 ± 5.80-4.5 ± 3.542.4 ± 11.99-2.1 ± 7.36
SecondaryChange From Baseline in Temperature

Temperature was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline and up to Week 14
Reported as:
Mean · degree Celsius
Change From Baseline in Temperature
degree CelsiusGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Week 1, n=36, 38, 37, 38, 35, 370.01 ± 0.356-0.00 ± 0.336-0.03 ± 0.2710.07 ± 0.401-0.03 ± 0.548-0.03 ± 0.468
Week 2, n=36, 36, 36, 38, 31, 350.03 ± 0.395-0.01 ± 0.410-0.01 ± 0.3140.19 ± 0.442-0.17 ± 0.4730.03 ± 0.384
Week 4, n=31, 34, 35, 38, 29, 310.05 ± 0.4450.11 ± 0.3850.06 ± 0.3330.07 ± 0.318-0.04 ± 0.4050.03 ± 0.439
Week 8, n=29, 31, 32, 38, 27, 26-0.02 ± 0.5030.17 ± 0.3340.12 ± 0.3450.17 ± 0.4530.14 ± 0.4730.11 ± 0.473
Week 12, n=26, 30, 32, 36, 26, 250.02 ± 0.3430.14 ± 0.4230.12 ± 0.4290.18 ± 0.5200.02 ± 0.4920.12 ± 0.561
Week 14, n=29, 31, 33, 34, 27, 26-0.04 ± 0.3720.10 ± 0.3640.01 ± 0.4560.11 ± 0.406-0.03 ± 0.5220.00 ± 0.591
EW, n=10, 7, 4, 2, 10, 90.12 ± 0.466-0.09 ± 0.3390.22 ± 0.3300.25 ± 0.7780.30 ± 0.533-0.27 ± 0.255
SecondaryNumber of Participants With Vital Signs of Clinical Importance

The vital signs including SBP, DBP and pulse rate were measured from Baseline throughout the study. The number of participants with clinically significant abnormal vital signs were presented. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 14
Reported as:
Number · Participants
Number of Participants With Vital Signs of Clinical Importance
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
SBP, Baseline, n=38, 38, 38, 38, 37, 38020110
SBP, Week 1, n=36, 38, 37, 38, 35, 37010100
SBP, Week 2, n=36, 36, 36, 38, 31, 35010001
SBP, Week 4, n=32, 34, 35, 38, 29, 31010110
SBP, Week 8, n=30, 31, 33, 38, 27, 26000200
SBP, Week 12, n=26, 30, 32, 36, 26, 25100100
SBP, Week 14, n=29, 31, 33, 34, 27, 26000000
SBP, EW, n=10, 7, 4, 2, 10, 9110000
SBP, PS, n=n=38, 38, 38, 38, 37, 38230211
DBP, Baseline, n=38, 38, 38, 38, 37, 38000100
DBP, Week 1, n=36, 38, 37, 38, 35, 37000101
DBP, Week 2, n=36, 36, 36, 38, 31, 35211001
DBP, Week 4, n=32, 34, 35, 38, 29, 31001001
DBP, Week 8, n=30, 31, 33, 38, 27, 26011001
DBP, Week 12, n=26, 30, 32, 36, 26, 25101201
DBP, Week 14, n=29, 31, 33, 34, 27, 26000000
DBP, EW, n=10, 7, 4, 2, 10, 9010000
DBP, PS, n=38, 38, 38, 38, 37, 38221301
Pulse rate, Baseline, n=38, 38, 38, 38, 37, 38000000
Pulse rate, Week 1, n=36, 38, 37, 38, 35, 37000010
Pulse rate, Week 2, n=36, 36, 36, 38, 31, 35000000
Pulse rate, Week 4, n=32, 34, 35, 38, 29, 31000010
Pulse rate, Week 8, n=30, 31, 33, 38, 27, 26000000
Pulse rate, Week 12, n=26, 30, 32, 36, 26, 25000010
Pulse rate, Week 14, n=29, 31, 33, 34, 27, 26000000
Pulse rate, EW, n=10, 7, 4, 2, 10, 9000000
Pulse rate, PS, n=38, 38, 38, 38, 37, 38011010
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Single 12-lead ECGs were obtained over a brief recording period at each specified time point during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. For multiple ECGs at one visit, or "Any time post-screen", a participant is categorized as "Abnormal" if \>=1 assessment is abnormal. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Up to Week 14
Reported as:
Number · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Baseline, n=38, 38, 38, 38, 37, 38586465
Week 1, n=36, 38, 37, 37, 34, 37487454
Week 12, n=26, 30, 32, 36, 26, 25267444
Week 14, n=29, 31, 33, 34, 27, 252510523
EW, n=10, 6, 4, 2, 10, 9130001
PS, n=38, 38, 38, 38, 36, 3771110777

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment until the Follow up Visit 2 at Week 16.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK2894512 1% BID0/38 (0%)1/38 (2.6%)17/38 (44.7%)
GSK2894512 1% QD0/38 (0%)3/38 (7.9%)12/38 (31.6%)
GSK2894512 0.5% BID0/38 (0%)3/38 (7.9%)11/38 (28.9%)
GSK2894512 0.5% QD0/38 (0%)0/38 (0%)11/38 (28.9%)
Vehicle BID0/37 (0%)0/37 (0%)3/37 (8.1%)
Vehicle QD0/38 (0%)0/38 (0%)3/38 (7.9%)
Most frequent serious events
Most frequent serious events
EventGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
Atrial fibrillationCardiac disorders0/380/381/380/380/370/38
Cardiac failure acuteCardiac disorders0/380/381/380/380/370/38
Coronary artery diseaseCardiac disorders0/381/380/380/380/370/38
Alcoholic pancreatitisGastrointestinal disorders1/380/380/380/380/370/38
Enlarged uvulaGastrointestinal disorders0/381/380/380/380/370/38
Hemolytic uremic syndromeBlood and lymphatic system disorders0/381/380/380/380/370/38
DehydrationMetabolism and nutrition disorders0/380/381/380/380/370/38
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/380/381/380/380/370/38
Most frequent other events
Most frequent other events
EventGSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QD
FolliculitisInfections and infestations8/382/384/385/381/370/38
NasopharyngitisInfections and infestations1/380/384/382/380/372/38
HeadacheNervous system disorders4/381/380/381/381/371/38
Dermatitis contactSkin and subcutaneous tissue disorders4/384/381/383/380/370/38
VomitingGastrointestinal disorders0/380/383/380/381/370/38
Application site dermatitisGeneral disorders1/382/380/380/380/370/38
AcneSkin and subcutaneous tissue disorders2/380/381/380/380/370/38
Dermatitis allergicSkin and subcutaneous tissue disorders2/380/380/380/380/370/38
MiliariaSkin and subcutaneous tissue disorders0/382/380/381/380/370/38
UrticariaSkin and subcutaneous tissue disorders0/382/380/380/380/370/38

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QDTotal
Mean45.9 ± 11.9348.5 ± 10.5649.6 ± 10.9348.7 ± 9.7246.7 ± 12.6246.4 ± 10.1647.6 ± 10.99
Sex: Female, Male
Sex: Female, Male(Participants)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QDTotal
Female1212141314974
Male262624252329153
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK2894512 1% BIDGSK2894512 1% QDGSK2894512 0.5% BIDGSK2894512 0.5% QDVehicle BIDVehicle QDTotal
Race, Customized — American Indian (Amer Ind)/Alaska Native (Ala Nat)0001001
Race, Customized — Asian/South East Asian Descent/Japanese Descent109869648
Race, Customized — Black/African American (Afr Amer)12313010
Race, Customized — White/Caucasian262726302532166
Race, Customized — Amer Ind/Ala Nat & Black/Afr Amer &White/Caucasian0010001
Race, Customized — Black/Afr Amer & White/Caucasian1000001
08

Study locations

46 sites
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    North Logan, Connecticut 06032, United States
  • GSK Investigational Site
    Miami, Florida 33142, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Plainfield, Indiana 46168, United States
  • GSK Investigational Site
    Overland Park, Kansas 66215, United States
  • GSK Investigational Site
    Louisville, Kentucky 40217, United States
  • GSK Investigational Site
    Fort Gratiot Township, Michigan 48059, United States
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Johnston, Rhode Island 02919, United States
  • GSK Investigational Site
    Goodlettsville, Tennessee 37072, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Webster, Texas 77598, United States
  • GSK Investigational Site
    Seattle, Washington 98101, United States
  • GSK Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 1V6, Canada
  • GSK Investigational Site
    Markham, Ontario L3P1X2, Canada
  • GSK Investigational Site
    North Bay, Ontario P1B 3Z7, Canada
  • GSK Investigational Site
    Oakville, Ontario L6J 7W5, Canada
  • GSK Investigational Site
    Ottawa, Ontario K2G 6E2, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9J5K2, Canada
  • GSK Investigational Site
    Richmond Hill, Ontario L4B 1A5, Canada
  • GSK Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • GSK Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • GSK Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • GSK Investigational Site
    Montreal, Quebec H2K 4L5, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1V4X7, Canada
  • GSK Investigational Site
    Fukuoka, 813-0044, Japan
  • GSK Investigational Site
    Fukuoka, 819-0373, Japan
  • GSK Investigational Site
    Hokkaido, 006-0022, Japan
  • GSK Investigational Site
    Hokkaido, 066-0021, Japan
  • GSK Investigational Site
    Hokkaido, 066-0064, Japan
  • GSK Investigational Site
    Kanagawa, 221-0825, Japan
  • GSK Investigational Site
    Kumamoto, 861-3101, Japan
  • GSK Investigational Site
    Osaka, 572-0838, Japan
  • GSK Investigational Site
    Osaka, 593-8324, Japan
  • GSK Investigational Site
    Tokyo, 133-0057, Japan
  • GSK Investigational Site
    Tokyo, 136-0074, Japan
  • GSK Investigational Site
    Tokyo, 190-0023, Japan
  • GSK Investigational Site
    Tokyo, 194-0013, Japan
  • GSK Investigational Site
    Tokyo, 195-0053, Japan
  • GSK Investigational Site
    Tokyo, 203-0003, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2015
First posted
Sep 30, 2015
Start
Nov 23, 2015
Primary completionActual
Oct 1, 2016
CompletionActual
Oct 5, 2016
Results first posted
Nov 13, 2017
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02564042
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 30, 2015
Start date
Nov 23, 2015
Primary completion
Oct 1, 2016
Completion
Oct 5, 2016
Results posted
Nov 13, 2017
Last update
Nov 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion